Donor–Acceptor Cyclopropanes as 1,2-Dipoles in GaCl₃-Mediated [4 + 2]-Annulation with Alkenes: Easy Access to the Tetralin Skeleton

Roman A. Novikov,^{†,‡} Anna V. Tarasova,[†] Victor A. Korolev,[†] Evgeny V. Shulishov,[†] Vladimir P. Timofeev,[‡] and Yury V. Tomilov^{*,†}

[†]N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky Prospekt, 119991 Moscow, Russian Federation

[‡]V. A. Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 32 Vavilov Street, 119991 Moscow, Russian Federation

Supporting Information

ABSTRACT: A new process for (4 + 2)-annulation of donor-acceptor cyclopropanes (DACs) with unsaturated compounds in the presence of anhydrous GaCl₃ has been developed. In this process, DACs act as sources of formal 1,2- and 1,4-dipoles to give polysubstituted tetralins in high yields and with high regio- and diastereoselectivity. Alkenes with both aryl and alkyl substituents at the double bond undergo this reaction equally readily. A most likely mechanism of the reaction has been proposed. It involves preliminary generation of a key 1,2-dipolar gallium complex and its subsequent participation in annulation with an alkene.



INTRODUCTION

Donor–acceptor cyclopropanes (DACs) are widely used in contemporary organic synthesis as carbon-based building blocks for the construction of various carbo- and heterocyclic compounds, including enantioselective reactions and full syntheses of natural compounds.^{1,2} They can act as synthetic equivalents of 1,3-dipoles and undergo cycloaddition and annulation with diverse substrates under acid catalysis conditions. Owing to this feature, they are currently very popular among chemists who deal with organic synthesis all over the world. However, though the scope of reactions involving DACs is very broad and diverse, their reactivity known to date is limited to use as 1,3-dipoles only.¹

We have recently discovered a new type of DAC reactivity, where they can act as sources of formal 1,2- and 1,4-dipoles in the presence of anhydrous GaCl₃ due to positive charge migration from the benzyl center.^{3,4} This type of reactivity was demonstrated for dimerization of 2-arylcyclopropane-1,1-dicarboxylates,³ which considerably limited its applicability to the use of these substrates. In this study, we expanded the use of DACs as formal 1,2- and 1,4-dipoles to their reactions with various unsaturated substrates.

In general, reactions of DACs with alkenes in the presence of Lewis acids have been known for a long time. They are widely used today in organic synthesis to build five-membered carbocycles.^{1a,h,5} These reactions are known to follow two pathways, namely, (3 + 2)-cycloaddition to give substituted cyclopentanes^{5a-e} and (3 + 2)-annulation to an aromatic substituent in DACs to give substituted indanes^{5f} (Scheme 1). Both variants involve initial generation of a highly reactive 1,3-

Scheme 1. Reactions of DACs with Alkenes in the Presence of a Lewis Acid



dipole. In this study, we have developed a new pathway of DAC reactions with alkenes, namely, (4 + 2)-annulation, where DACs, specifically 2-arylcyclopropane-1,1-dicarboxylates, act as formal 1,4-dipoles that react with alkenes to give substituted tetralins. This change in reactivity is achieved by using anhydrous GaCl₃ and a specially developed approach for selective generation of 1,2-dipoles.^{3b}

The (4 + 2)-annulation of DACs developed by us is a synthetically valuable process that allows one-stage syntheses of polysubstituted tetralins with high regio- and diastereoselectivity from simple and readily available 2-arylcyclopropanedicar-

 Received:
 June 8, 2015

 Published:
 July 18, 2015

boxylates and unsaturated compounds. The latter may be of interest as synthons in organic synthesis and as compounds possessing biological activity. In fact, aryltetralin moieties are found in the structures of a number of compounds that were isolated from various natural sources and that manifest a broad spectrum of biological activity,⁶ including antitumor activity^{6f} (Figure 1).



RESULTS AND DISCUSSION

To implement the reactions of DACs with alkenes by the selective (4 + 2)-annulation pathway, we had to perform a detailed and thorough adjustment of the process conditions. As a result, the nature of the reaction intermediates changed. We studied the reaction of dimethyl 2-phenylcyclopropanedicarboxylate (1a) with styrene (2a) as a model reaction for optimization (Table 1).

It was found that if one just mixes cyclopropane 1a with styrene in the presence of $GaCl_3$, then cyclopentane 3a, a (3 + 2)-cycloaddition product, is mainly formed (method A). However, if one prepares relatively stable 1,2-dipolar gallium complex 4a and then performs its reaction with the alkene, then tetralin derivative 5a is formed as the main reaction product (Scheme 2). Thus, the most important condition for the reaction to follow the (4 + 2)-annulation pathway is the preliminary generation of 1,2-dipole 4a (Table 1, method B), which changes the direction of the reaction. We have shown previously^{3b} that the optimum conditions for generation of this intermediate include the use of equimolar amounts of a DAC and anhydrous GaCl₃ in dichloromethane at 0-5 °C. In this case, intermediate 4a was detected by NMR spectroscopy and was shown to exist in rather narrow temperature and time ranges.

Furthermore, we studied a series of 2-arylcyclopropane-1,1dicarboxylates and various unsaturated compounds that react by (4 + 2)-annulation (Scheme 2). It has been found that reactions in the presence of GaCl₃ to give polysubstituted tetralins **5** are of general scope and apply to alkenes with both aryl and alkyl substituents at the double bond, as well as arylcyclopropanedicarboxylates with various substituents at the aromatic ring. In this case, the process conditions depend on the substrate type quite insignificantly. Table 1. Optimization of the Reaction Conditions for the Model (4 + 2)-Annulation between Cyclopropane 1a and Styrene (2a) in the Presence of GaCl₃



ntry	mol %	equiv	°Č	min	°C	t _{ii} , h	3a	5a
1 ^{<i>c</i>}	120	3	20		40	1	95	0
2	120	3	0	0.5	40	2	87	6
3	100	3	0	15	40	2	5 ^b	70 ^b
4	110	3	5	8	40	2	0	76 ^b
5	150	3	0	10	40	2	0	53 ^{b,d}
6	105	1	0	10	40	2	5 ^b	40 ^{b,d}
7	110	5	0	10	40	2	0	85
8	100	3	0	10	20	2.5	41 ^b	33 ^b
9 ^e	105	3	0	10	40	2	80 ^b	10 ^b

^{*a*}Product yields strongly depend on the quality of GaCl₃ used and the traces of moisture. ^{*b*}NMR yields. ^{*c*}Method A was used. ^{*d*}The dimers of starting cyclopropane 1a are formed in a large quantity (see refs 3b and 4e). ^{*c*}Water traces were used in the reaction mixture after the first step by the short contact with air.

In fact, styrenes with substituents at the aromatic ring (2b-e) underwent this process rather well; however, the yields of the corresponding tetralins 5b-e turned out to be noticeably smaller than in the case of nonsubstituted styrene, probably due to easier polymerization of substituted styrenes in the presence of GaCl₃. All disubstituted tetralins 5a-e were formed as mixtures of *cis*- and *trans*-isomers in a (2-7):1 ratio, with the *cis*-isomer predominating. The reaction with 1a also occurs with methoxy-substituted styrenes 2d,e. This is particularly valuable despite the moderate yields of the resulting tetralins 5d,e, since tetralins with alkoxy substituents at the aromatic rings are widespread in nature and have a broad spectrum of biological activity.⁶

(4 + 2)-Annulation of 1a readily occurs with α - and β -alkylor aryl-substituted styrenes 2g,h,j,k, as well as with monosubstituted and gem-disubstituted alkenes (hex-1-ene and 2methylpropene). In the latter two cases, the yields of products 5f and 5i reached 93% and 86%, respectively. Tetralin 5f unexpectedly formed to favor the *trans*-isomer in contrast to tetralins 5a-e. The reactions with cycloalkenes gave fused tetralins 51-o in 40-53% yields. In this case, the reactions of 1a with *trans*-stilbene, 1-phenylcyclohexene, cyclohexene, and dihydronaphthalene gave the respective tetralins 5j,l,m,o, each as a single diastereomer.

Reaction of (4 + 2)-annulation can also be carried out with more complex unsaturated substrates. In fact, styrylmalonates **2p,q** react fairly well with 1,2-dipoles that are formed from 2phenyl- and 2-(4-fluorophenyl)cyclopropanedicarboxylates **1a,b** Scheme 2. Scope of (4 + 2)-Annulation of Cyclopropanes 1 to Alkenes 2^{a}



^{*a*}Reaction conditions: (i) $0-5 \,^{\circ}$ C, GaCl₃ (1.0–1.1 equiv for 1a-d, f, 1.2–1.5 equiv for 1e), time 8–15 min for 1a-c, f, 20–30 min for 1d, and 30–60 min for 1e; (ii) 40 $^{\circ}$ C, 1–3 h. Excess of alkenes: 1–1.2 equiv for tetralins 5i, p–r, 2 equiv for tetralin 5f, 3–5 equiv for tetralins 5a–e, g, h, j–l, o, and 5–8 equiv for tetralins 5m, n, s–x.

in the presence of GaCl₃ to give polysubstituted tetralins 5p-r as single diastereomers, which in essence are formal homodimers and cross-dimers of the starting cyclopropanes.^{3b} It should be noted that, in the case of nonsymmetric alkenes, all the reactions of 1,2-dipole addition studied occur with exclusively high regioselectivity, in agreement with the more efficient stabilization of the carbocationic center in the intermediate, which allows the synthesis of substituted tetralins to be performed on a sufficiently preparative scale.

Besides unsaturated compounds, the substituents in the starting cyclopropane 1 in (4 + 2)-annulation can also be varied. In fact, 4-fluoro- and 4-chloro-substituted cyclopropanes **1b**,**c** readily react with styrene, though in this case one has to use an even greater excess of styrene due to easier dimerization of the starting cyclopropanes. Arylcyclopropanes with a chlorine atom at the *meta* and *ortho* positions of the phenyl substituent (**1d**,**e**) can also be used in this reaction. However, due to their lower reactivity in comparison with that of unsubstituted phenylcyclopropane **1a**, especially in the case of the *o*-chlorophenyl substituent, the time for generation of 1,2-dipoles **4d**,**e** has to be increased considerably. As a result, the

efficiency of generation decreases, and side processes occur during this long time; hence, the yields of the target tetralins decrease. However, as such, the new approach to the synthesis of substituted tetralins is rather successful. It is interesting to note that the structurally identical moiety in *m*-chlorophenylsubstituted cyclopropane **1d** gives only regioisomer **5v** in the same reaction with styrene; i.e., annulation occurs only at the less sterically hindered position.

The reaction of dimethyl 2-naphthylcyclopropanedicarboxylate (1f) with styrene in the presence of $GaCl_3$ has to be noted separately. In this case, (4 + 2)-annulation is also the predominating process; however, since electrophilic attack on the naphthyl ring can occur at two different adjacent positions, the reaction gives two different regioisomers, **5w** and **5x**, in a 1:1.5 ratio.

The composition of all the target products was established by means of elementary analyses or HRMS. The structure and stereochemistry of the compounds obtained were determined by ¹H, ¹⁹F, and ¹³C NMR spectroscopy using 1D and 2D DEPT, COSY, TOCSY, NOESY, HMQC/HSQC, and HMBC (for details, see the Supporting Information).

On the basis of previous experimental data^{3a,b} and the data obtained in this study, it is obvious that (4 + 2)-annulation of DACs with alkenes occurs via the key 1,2-dipolar gallium complex 4 formed by DAC opening to give a classic 1,3-dipole, 6, followed by positive charge migration from the benzyl position in the presence of GaCl₃. In this case, 1,2-dipole 4 exists in equilibrium with 1,3-dipole 6. This equilibrium is strongly shifted toward the 1,2-dipole^{3a,b} (Scheme 3).





The two dipoles have different reactivities. In particular, this fact allows the existence of a 1,2-dipolar gallium intermediate to be observed experimentally for a few hours, unlike in the case of the 1,3-dipole. As a consequence, full generation of the 1,2-dipole and its subsequent reaction with an unsaturated compound are the key stages for the synthesis of tetralins substituted in a certain way.

After the formation of the 1,2-dipole and addition of an unsaturated compound, intermediate 7 is formed at an elevated temperature. In this case, addition of the carbocationic center in the 1,2-dipole to the double bond in the alkene occurs in such a way that the positive charge is located at the benzyl position in the case of styrenes or at the most substituted carbon atom in the case of alkenes, which explains the exceptional regiose-lectivity of the reaction. After that, intermediate 7 undergoes intramolecular electrophilic substitution at the aromatic ring to give the final tetralin 5, which is also facilitated by an increase in temperature. At reduced temperatures, tetralins 5 are not formed at all or are formed in minor amounts. Instead of (4 + 2)-annulation, the resulting 1,2-dipole 4 gradually regenerates 1,3-dipole 6, which instantly reacts with dipole 4 and an alkene available in the system to give (3 + 2)-cycloaddition products.

CONCLUSION

We have discovered a new regio- and diastereoselective (4 + 2)annulation of aryl-substituted DACs with alkenes to give polysubstituted tetralins and developed the corresponding preparative technique. The process occurs only in the presence of anhydrous gallium trichloride and involves preliminary generation of a 1,2-dipolar gallium complex. The reaction is of general scope and applies to diverse unsaturated compounds, with both aryl and alkyl substituents at the double bond, as well as DACs with substituents at various aromatic ring positions. This process is a unique example where DACs are used as sources of formal even-numbered 1,2- and 1,4-dipoles in reactions with unsaturated substrates.

EXPERIMENTAL SECTION

General Experimental Details. All reagents and solvents used were commercial grade chemicals without additional purification. All operations with GaCl₃ were carried out under a dry argon atmosphere. TLC analysis was performed on Silufol chromatographic plates. For preparative chromatography, silica gel 60 (0.040-0.063 mm) was used. ¹H and ¹³C{¹H} NMR spectra were recorded on 400 MHz (400.1 and 100.6 MHz, respectively) and 300 MHz (300.1 and 75.5 MHz, respectively) spectrometers in CDCl₃ containing 0.05% Me₄Si as the internal standard. Determinations of the structures and stereochemistry of the obtained compounds and assignments of the ¹H and ¹³C signals were made with the aid of 1D and 2D DEPT, JMOD, COSY, TOCSY, NOESY, XHCORR, HSQC, and HMBC spectra. ¹⁹F NMR spectra were recorded on a 300 MHz spectrometer (282.4 MHz; standard CFCl₃). Determinations of the structures and assignments of the ¹⁹F signals were made with the aid of 2D ¹H,¹⁹F HMQC, and HMBC spectra. Monitoring of the reactions in an NMR tube was done in a CD₂Cl₂ solution containing 0.05% Me₄Si as the internal standart. IR spectra were obtained on an FT-IR spectrometer in CHCl₃ solution (1%). Mass spectra were recorded using electron impact ionization (EI; 70 eV, direct inlet probe). High-resolution mass spectra (HRMS TOF) were obtained using simultaneous electospray ionization (ESI). The elemental compositions were determined on a CHN analysis instrument.

General Procedure for the Synthesis of Cyclopropanes 1a–f and Alkenes 2p,q. Starting cyclopropanes 1a–f were synthesized from the corresponding aromatic aldehydes through a standard synthetic sequence of Knoevenagel/Corey–Chaykovsky reactions.^{3b,4c} (*E*)-Dimethyl 2-styrylmalonate (2p) and (*E*)-dimethyl 2-(4-fluorostyryl)malonate (2q) were synthesized from the corresponding DACs 1a,b through (TMS)OTf-mediated isomerization.⁷

General Procedure for the Synthesis of Tetralins 5a-y. Solid $GaCl_3$ (1–1.5 equiv) in one portion was added at 0 °C to a solution of cyclopropane 1 (0.5-1.0 mmol) in dry CH₂Cl₂ (3-5 mL), and the mixture was stirred at the same temperature until completion of the generation of 1,2-dipole 4 (optimal conditions: 1 equiv of GaCl₃, 10-15 min, for cyclopropanes 1a-c,f; 1.1-1.2 equiv of GaCl₃, 20-30 min, for cyclopropane 1d; 1.2-1.5 equiv of GaCl₃, 40-60 min, for cyclopropane 1e). Then a solution of alkene 2 (1-8 equiv) in dry CH_2Cl_2 (1-2 mL) was added, and the reaction mixture was immediately heated to 40 °C and refluxed for 1-3 h until reaction completion. After that, an aqueous solution of HCl (5%) was added at room temperature until pH 3 was achieved, and the reaction mixture was extracted with CH_2Cl_2 (3 × 10–15 mL). The organic layer was dried over MgSO₄, and the solvent was removed in vacuo. The residue was purified by column chromatography on silica gel (benzene-EtOAc, 50:1 to 10:1) to afford the title tetralin 5 as a thick colorless oil. If necessary, the resulting compound 5 may be additionally purified on a Silufol chromatographic plate (20 \times 20 cm), eluting with hexane-acetone (5:1) or benzene-EtOAc (10:1) to give a pure product.

cis- and *trans*-2-(1,3-Dimethoxy-1,3-dioxopropan-2-yl)-4phenyl-1,2,3,4-tetrahydronaphthalene (5a). The title compound was prepared according to the general procedure as a mixture of diastereomers (*cis:trans* = 2:1) from cyclopropane 1a (234 mg, 1.0 mmol), styrene (2a) (520 mg, 5 mmol), and GaCl₃ (194 mg, 1.1 mmol) in 287 mg yield (85%). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3020, 2955, 2927, 1732 br (O=CO), 1601, 1582, 1516, 1493, 1451, 1437 cm⁻¹. MS (*m*/*z* (rel intens, %))): 338 (6, M⁺), 307 (10, M⁺ – OCH₃), 275 (3), 206 (100), 191 (22), 178 (30), 165 (15), 128 (27), 115 (16), 91 (32), 59 (31). HRMS: calcd for C₂₁H₂₂O₄ M + H 339.1591, M + Na 361.1410, found *m*/*z* 339.1590, 361.1409.

The following are data for compound *cis*-**5a** (major isomer). ¹H NMR (CDCl₃, 400.1 MHz): δ 1.67 (ddd, 1H, *syn*-H(3), ²*J* = 12.6 Hz, ³*J* = 12.3 and 12.1 Hz), 2.17 (dddd, 1H, *anti*-H(3), ²*J* = 12.6 Hz, ³*J* = 5.4 and 2.6 Hz, ⁴*J* = 2.2 Hz), 2.68–2.76 (m, 1H, H(2)), 2.82 (dd, 1H, *anti*-H(1), ²*J* = 15.5 Hz, ³*J* = 11.7 Hz), 2.93 (ddd, 1H, *syn*-H(1), ²*J* = 15.5 Hz, ⁴*J* = 2.2 Hz), 3.38 (d, 1H, CH, ³*J* = 8.4 Hz), 3.72 and 3.77 (both s, 2 × 3H, 2 OMe), 4.12 (dd, 1H, H(4), ³*J* = 12.1 and

5.4 Hz), 6.75 (br d, 1H, H(5), ${}^{3}J$ = 7.6 Hz), 7.00 (m, 1H, H(6)), 7.07 (m, 1H, H(7)), 7.08 (m, 1H, H(8)), 7.16 (m, 2H, 2 *o*-H), 7.24 (m, 1H, *p*-H), 7.29 (m, 2H, 2 *m*-H). ${}^{13}C{}^{1}H$ NMR (CDCl₃, 100.6 MHz): δ 34.3 (CH₂(1)), 35.1 (CH(2)), 38.4 (CH₂(3)), 46.9 (CH(4)), 52.51 and 52.54 (2OMe), 57.4 (CH(2')), 126.1 (2C, CH(6) and CH(8)), 126.5 (*p*-CH), 128.6 (2 *m*-CH), 128.86 (2 *o*-CH), 128.90 (CH(7)), 129.5 (CH(5)), 135.7 (C(8a)), 139.3 (C(4a)), 146.4 (*i*-C), 168.7 and 168.8 (2COO).

The following are data for compound *trans*-**5a** (minor isomer). ¹H NMR (CDCl₃, 400.1 MHz): δ 1.96–2.05 (m, 2H, CH₂(3)), 2.60–2.67 (m, 1H, H(2), ³J = 9.8, 8.4, 4.6 Hz), 2.72 (dd, 1H, *syn*-H(1), ²J = 16.2 Hz, ³J = 9.8 Hz), 3.03 (dd, 1H, *anti*-H(1), ²J = 16.2 Hz, ³J = 4.6 Hz), 3.36 (d, 1H, CH, ³J = 8.4 Hz), 3.65 and 3.69 (both s, 2 × 3H, 2 OMe), 4.29 (dd, 1H, H(4), ³J = 5.3 and 5.1 Hz), 6.94 (br d, 1H, H(5), ³J = 7.6 Hz), 7.00 (m, 2H, 2 o-H), 7.11 (m, 1H, H(6)), 7.14 (m, 1H, H(8)), 7.15 (m, 1H, H(7)), 7.17 (m, 1H, *p*-H), 7.25 (m, 2H, 2 *m*-H). ¹³C{¹H} NMR (CDCl₃, 100.6 MHz): δ 30.2 (CH(2)), 32.3 (CH₂(1)), 36.0 (CH₂(3)), 43.6 (CH(4)), 52.35 and 52.38 (2OMe), 56.3 (CH(2[′])), 126.1 (CH(6)), 126.2 (*p*-CH), 126.4 (CH(8)), 128.2 (2 *m*-CH), 128.7 (2 *o*-CH), 129.2 (CH(7)), 130.4 (CH(5)), 136.0 (C(8a)), 137.6 (C(4a)), 146.6 (*i*-C), 168.7 and 168.9 (2COO).

cis- and *trans*-2-(1,3-Dimethoxy-1,3-dioxopropan-2-yl)-4-(4methylphenyl)-1,2,3,4-tetrahydronaphthalene (5b). The title compound was prepared according to the general procedure from cyclopropane 1a (150 mg, 0.64 mmol), 4-methylstyrene (2b) (378 mg, 3.20 mmol), and GaCl₃ (118 mg, 0.67 mmol) as a mixture of diastereomers (*cis*:*trans* = 4.5:1) in 88 mg yield (39%). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3011, 2955, 2926, 1733 (O=CO), 1514, 1493, 1450, 1436 cm⁻¹. MS (*m*/*z* (rel intens, %)): 352 (4, M⁺), 321 (2, M⁺ – OCH₃), 220 (100), 205 (30), 178 (14), 128 (23), 105 (38), 91(11), 59 (15). HRMS: calcd for C₂₂H₂₄O₄ M + H 353.1747, M + Na 375.1567, 391.1306, found *m*/*z* 353.1749, 375.1562.

The following are data for compound *cis*-**5b** (major isomer). ¹H NMR (CDCl₃, 400.1 MHz): δ 1.59 (ddd, 1H, *syn*-H(3), ²*J* = 12.5 Hz, ³*J* = 12.3, 12.1 Hz), 2.08 (ddd, 1H, *anti*-H(3), ²*J* = 12.5 Hz, ³*J* = 5.4 and 2.9 Hz, ⁴*J* = 2.3 Hz), 2.26 (s, 3H, Me), 2.61–2.69 (m, 1H, H(2)), 2.74 (dd, 1H, *anti*-H(1), ²*J* = 15.4 Hz, ³*J* = 11.7 Hz), 2.85 (ddd, 1H, *syn*-H(1), ²*J* = 15.4 Hz, ³*J* = 4.3 Hz, ⁴*J* = 2.3 Hz), 3.29 (d, 1H, CH, ³*J* = 8.4 Hz), 3.65 and 3.70 (both s, 2 × 3H, 2 OMe), 4.02 (dd, 1H, H(4), ³*J* = 12.1 and 5.4 Hz), 6.69 (br d, 1H, H(5), ³*J* = 7.6 Hz), 6.90–6.95 (m, 1H, H(6)), 6.95–7.07 (m, 6H, 2Ar except H(5) and H(6)). ¹³C{¹H} NMR (CDCl₃, 100.6 MHz): δ 21.2 (CH₃), 33.3 (CH₂(1)), 35.2 (CH(2)), 38.6 (CH₂(3)), 46.6 (CH(4)), 52.60 and 52.63 (2OMe), 57.6 (CH), 126.15 and 126.17 (CH(6) and CH(8)), 128.8 (2 *m*-CH), 128.9 (CH(7)), 129.3 (2 *o*-CH), 129.6 (CH(5)), 135.7 (*p*-C), 136.1 (C(8a)), 139.6 (C(4a)), 143.5 (*i*-C), 168.8 and 168.9 (2COO).

The following are data for compound *trans*-**5b** (minor isomer). ¹H NMR (CDCl₃, 400.1 MHz): δ 1.90–1.97 (m, 2H, CH₂(3)), 2.23 (s, 3H, Me), 2.52–2.62 (m, 1H, H(2)), 2.59–2.67 (m, 1H, *syn*-H(1)), 2.96 (dd, 1H, *anti*-H(1), ³J = 16.0 and 4.6 Hz), 3.29 (d, 1H, H(2'), ³J = 8.3 Hz), 3.59 and 3.63 (both s, 2 × 3H, 2 OMe), 4.17 (dd, 1H, H(4), ³J = 5.3 and 5.1 Hz), 6.81 (br d, 1H, H(5), ³J = 8.0 Hz), 6.84–7.07 (m, 7H, 2Ar except H(5)). ¹³C{¹H} NMR (CDCl₃, 100.6 MHz): δ 21.1 (CH₃), 30.3 (CH₂(1)), 33.3 (CH(2)), 36.0 (CH₂(3)), 43.3 (CH(4)), 52.46 and 52.48 (2OMe), 56.4 (CH)), 126.3 and 126.5 (CH(6) and CH(8)), 128.6, 129.1, 129.3, and 129.6 (2 *o*-CH, 2 *m*-CH, CH(5) and CH(7)), 135.6 (*p*-C), 135.9 (C(8a)), 137.9 (C(4a)), 143.7 (*i*-C), 168.9 and 169.0 (2COO).

cis- and *trans*-2-(1,3-Dimethoxy-1,3-dioxopropan-2-yl)-4-(4*tert*-butylphenyl)-1,2,3,4-tetrahydronaphthalene (5c). The title compound was prepared according to the general procedure from cyclopropane 1a (150 mg, 0.64 mmol), 4-(*tert*-butyl)styrene (2c) (512 mg, 3.20 mmol), and GaCl₃ (118 mg, 0.67 mmol) as a mixture of diastereomers (*cis:trans* = 2.5:1) in 120 mg yield (48%). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3008, 2958, 1732 (O=CO), 1451, 1437 cm⁻¹. MS (*m*/*z* (rel intens, %)): 394 (15, M⁺), 363 (4, M⁺ – OCH₃), 262 (100), 247 (28), 217 (9), 205 (100), 178 (16), 158 (40), 143 (49), 133 (63), 119 (25), 100 (19), 91(39), 69 (16), 57 (67). HRMS: calcd for $C_{25}H_{30}O_4$ M + H 395.2217, M + Na 417.2036, M + K 433.1776, found m/z 395.2214, 417.2033, 433.1775.

The following are data for compound *cis*-**5**c (major isomer). ¹H NMR (CDCl₃, 400.1 MHz): δ 1.32 (s, 9H, *t*-Bu), 1.65 (ddd, 1H, *syn*-H(3), ²*J* = 12.7 Hz, ³*J* = 12.2 and 12.2 Hz), 2.16 (dddd, 1H, *anti*-H(3), ²*J* = 12.7 Hz, ³*J* = 5.4 and 2.5 Hz, ⁴*J* = 2.1 Hz), 2.68–2.77 (m, 1H, H(2)), 2.81 (dd, 1H, *anti*-H(1), ³*J* = 15.5 and 11.7 Hz), 2.92 (ddd, 1H, *syn*-H(1), ²*J* = 15.5 Hz, ³*J* = 4.2 Hz, ⁴*J* = 2.1 Hz), 3.36 (d, 1H, CH, ³*J* = 8.5 Hz), 3.73 and 3.78 (both s, 2 × 3H, 2 OMe), 4.10 (dd, 1H, H(4), ³*J* = 12.2 and 5.4 Hz), 6.78 (br d, 1H, H(5), ³*J* = 7.8 Hz), 6.98–7.16 (m, 3H, H(6)–H(8)), 7.05–7.10 (m, 2H, 2 o-H), 7.28–7.33 (m, 2H, 2 m-H). ¹³C{¹H} NMR (CDCl₃, 100.6 MHz): δ 31.6 (CMe₃), 34.4 (CH₂(1)), 34.6 (CMe₃), 35.3 (CH(2)), 38.6 (CH₂(3)), 46.5 (CH(4)), 52.61 and 52.62 (2OMe), 57.6 (CH), 125.5 (2 m-CH), 126.11 and 126.14 (CH(6) and CH(8)), 128.5 (2 o-CH), 129.0 (CH(7)), 129.7 (CH(5)), 135.8 (C(8a)), 139.7 (C(4a)), 143.3 (*i*-C), 149.4 (*p*-C), 168.87 and 168.93 (2COO).

The following are data for compound *trans*-**5**c (minor isomer). ¹H NMR (CDCl₃, 400.1 MHz): δ 1.29 (s, 9H, *t*-Bu), 1.97–2.03 (m, 2H, CH₂(3)), 2.57–2.69 (m, 1H, H(2)), 2.66–2.76 (m, 1H, *syn*-H(1)), 3.04 (dd, 1H, *anti*-H(1), ³J = 15.9 and 4.5 Hz), 3.29 (d, 1H, CH, ³J = 8.3 Hz), 3.66 and 3.70 (both s, 2 × 3H, 2 OMe), 4.25 (dd, 1H, H(4), ³J ≈ 5.1 and 5.2 Hz), 6.90–6.94 (m, 2H, 2 *o*-H), 6.96 (br d, 1H, H(5), ³J = 7.5 Hz), 6.98–7.16 (m, 3H, H(6), H(7) and H(8)), 7.24–7.28 (m, 2H, 2 *m*-H). ¹³C{¹H} NMR (CDCl₃, 100.6 MHz): δ 30.5 (CH(2)), 31.6 (3 Me, *t*-Bu), 33.3 (CH₂(1)), 34.5 (C, *t*-Bu), 36.0 (CH₂(3)), 43.2 (CH(4)), 52.43 and 52.45 (2OMe), 56.5 (CH), 125.2 (2 *m*-CH), 126.2 (CH(6)), 126.4 (CH(8)), 128.4 (2 *o*-CH), 129.3 (CH(7)), 130.5 (CH(5)), 136.0 (C(8a)), 138.0 (C(4a)), 143.6 (*i*-C), 148.9 (*p*-C), 169.0 and 169.1 (2COO).

cis- and *trans*-2-(1,3-Dimethoxy-1,3-dioxopropan-2-yl)-4-(4methoxyphenyl)-1,2,3,4-tetrahydronaphthalene (5d). The title compound was prepared according to the general procedure from cyclopropane 1a (150 mg, 0.64 mmol), 4-methoxystyrene (2d) (429 mg, 3.20 mmol), and GaCl₃ (118 mg, 0.67 mmol) as a mixture of diastereomers (*cis:trans* = 3.5:1) in 86 mg yield (37%). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3007, 2956, 2839, 1751, 1732 (O=CO), 1610, 1512, 1437 cm⁻¹. MS (*m*/*z* (rel intens, %)): 368 (10, M⁺), 250 (31), 236 (100), 221 (14), 209 (15), 178 (14), 165 (14), 142 (22), 128 (39), 121 (48), 69 (12). HRMS: calcd for C₂₂H₂₄O₅ M + H 369.1697, M + Na 391.1516, found *m*/*z* 369.1691, 391.1515.

The following are data for compound *cis*-**5d** (major isomer). ¹H NMR (CDCl₃, 400.1 MHz): δ 1.64 (ddd, 1H, *syn*-H(3), ²*J* = 12.5 Hz, ³*J* = 12.0 and 12.1 Hz), 2.14 (dddd, 1H, *anti*-H(3), ²*J* = 12.5 Hz, ³*J* = 5.3 and 2.8 Hz, ⁴*J* = 2.2 Hz), 2.67–2.77 (m, 1H, H(2)), 2.76 (dd, 1H, *anti*-H(1), ²*J* = 15.0 Hz, ³*J* = 11.5 Hz), 2.92 (ddd, 1H, *syn*-H(1), ²*J* = 15.0 Hz, ³*J* = 7.8 Hz, ⁴*J* = 2.2 Hz), 3.37 (d, 1H, CH, ³*J* = 8.4 Hz), 3.73, 3.78, and 3.79 (all s, 3 × 3H, 3 OMe), 4.08 (dd, 1H, H(4), ³*J* = 12.1 and 5.3 Hz), 6.79 (br d, 1H, H(5), ³*J* = 7.8 Hz), 6.82–6.86 (m, 2H, 2 *m*-H), 6.98–7.10 (m, 3H, H(6)–H(8)), 7.06–7.10 (m, 2H, 2 *o*-H). ¹³C{¹H} NMR (CDCl₃, 100.6 MHz): δ 34.2 (CH₂(1)), 35.1 (CH(2)), 38.5 (CH₂(3)), 46.1 (CH(4)), 55.34, 52.55, and 52.57 (3 OMe), 57.5 (CH), 114.0 (2 *m*-CH), 126.1, 126.3 (CH(6) and CH(7)), 128.4 (CH(8)), 128.9 (2 *o*-CH), 129.4 (CH(5)), 135.6 (C(8a)), 139.6 (C(4a)), 145.1 (*i*-C), 158.2 (*p*-C), 168.7 and 168.8 (2COO).

The following are data for compound *trans*-**5d** (minor isomer). ¹H NMR (CDCl₃, 400.1 MHz): δ 1.96–2.01 (m, 2H, CH₂(3)), 2.57–2.68 (m, 1H, H(2)), 2.64–2.74 (m, 1H, *syn*-H(1)), 3.02 (dd, 1H, *anti*-H(1), ²J = 16.0 Hz, ³J = 4.3 Hz), 3.36 (d, 1H, H(2'), ³J = 8.4 Hz), 3.67, 3.71, and 3.77 (all s, 3 × 3H, 3 OMe), 4.24 (dd, 1H, H(4), ³J ≈ 5.0 and 5.1 Hz), 6.73–6.77 (m, 2H, 2 *m*-H), 6.86–6.89 (m, 2H, 2 *o*-H), 6.94 (br d, 1H, H(5), ³J = 8.0 Hz), 7.06–7.20 (m, 3H, H(6)–H(8)). ¹³C{¹H} NMR (CDCl₃, 100.6 MHz): δ 30.2 (CH(2)), 33.2 (CH₂(1)), 36.0 (CH₂(3)), 43.8 (CH(4)), 55.29, 52.38, and 52.42 (3 OMe), 56.4 (CH), 113.2 (2 *m*-CH), 126.2 and 126.3 (CH(6) and CH(8)), 128.2 (2 *o*-CH), 129.2 (CH(7)), 130.3 (CH(5)), 135.6 (C(8a)), 138.8 (C(4a)), 142.5 (*i*-C), 157.5 (*p*-C), 168.8 and 168.9 (2COO).

cis- and *trans*-2-(1,3-Dimethoxy-1,3-dioxopropan-2-yl)-4-(2-methoxyphenyl)-1,2,3,4-tetrahydronaphthalene (5e). The title compound was prepared according to the general procedure from cyclopropane 1a (150 mg, 0.64 mmol), 2-methoxystyrene (2e) (429 mg, 3.20 mmol), and GaCl₃ (118 mg, 0.67 mmol) as a mixture of diastereomers (*cis:trans* = 7:1) in 96 mg yield (42%). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3007, 2956, 2839, 1732 (O=CO), 1610, 1583, 1512, 1494, 1451, 1375, 1337, 1301, 1245 cm⁻¹. MS (*m*/*z* (rel intens, %)): 368 (11, M⁺), 250 (33), 236 (100), 221 (18), 209 (19), 178 (14), 165 (15), 142 (24), 128 (44), 121 (53), 108 (8), 100 (10), 91 (9), 59 (27). HRMS: calcd for C₂₂H₂₄O₅ M + NH₄ 386.1962, M + Na 391.1516, found: *m*/*z* 386.1960, 391.1512.

The following are data for compound *cis*-**5e** (major isomer). ¹H NMR (CDCl₃, 400.1 MHz): δ 1.70 (ddd, 1H, *syn*-H(3), ²*J* = 12.6 Hz, ³*J* = 12.1 and 11.9 Hz), 2.12 (dddd, 1H, *anti*-H(3), ²*J* = 12.6 Hz, ³*J* = 5.5 and 2.6 Hz, ⁴*J* = 2.2 Hz), 2.67–2.77 (m, 1H, H(2)), 2.81 (dd, 1H, *anti*-H(1), ²*J* = 15.3 Hz, ³*J* = 11.6 Hz), 2 0.91 (ddd, 1H, *syn*-H(1), ²*J* = 15.3 Hz, ³*J* = 4.1 Hz, ⁴*J* = 2.2 Hz), 3.38 (d, 1H, CH, ³*J* = 8.3 Hz), 3.73, 3.76, and 3.77 (all s, 3 × 3H, 3 OMe), 4.61 (dd, 1H, H(4), ³*J* = 11.9 and 5.5 Hz), 6.74 (br d, 1H, H(5), ³*J* = 7.6 Hz), 6.85–6.92 (m, 2H), 6.95–7.02 (m, 2H), 7.04–7.09 (m, 2H) and 7.17–7.23 (m, 1H) (2Ar except H(5)). ¹³C{¹H} NMR (CDCl₃, 100.6 MHz): δ 34.4 (CH₂(1)), 35.4 (CH(2)), 36.2 (CH₂(3)), 39.7 (br, CH(4)), 52.56 and 52.57 (2COOMe), 55.7 (OMe), 57.7 (CH), 111.2 (CH(3')), 121.0 (CH(5')), 125.7, 126.1, 127.6, 128.9, 129.0, and 129.8 (CH(5)–CH(8), CH(4') and CH(6')), 134.8 (C(1')), 135.9 (C(8a)), 139.7 (C(4a)), 157.7 (C(2'))), 168.94 and 169.02 (2COO).

The following are data for compound *trans*-**5e** (minor isomer). ¹H NMR (CDCl₃, 400.1 MHz): δ 1.90 (ddd, 1H, H_a(3), ²J = 13.1 Hz, ³J = 10.8 and 5.9 Hz), 1.97–2.04 (m, 2H, H_b(3)), 2.51–2.62 (m, 1H, H(2)), 2.65–2.72 (m, 1H, *syn*-H(1)), 3.01 (dd, 1H, *anti*-H(1), ²J = 16.3 Hz, ³J = 5.5 Hz), 3.35 (d, 1H, H(2'), ³J = 8.3 Hz), 3.68, 3.70, and 3.76 (all s, 3 × 3H, 3 OMe), 4.66 (dd, 1H, H(4), ³J = 5.9 and 3.6 Hz), 6.85–7.25 (m, 8H, 2 Ar).

cis- and *trans*-2-(1,3-Dimethoxy-1,3-dioxopropan-2-yl)-4-(1butyl)-1,2,3,4-tetrahydronaphthalene (5f). The title compound was prepared according to the general procedure from cyclopropane 1a (235 mg, 1.0 mmol), 1-hexene (2f) (176 mg, 2.1 mmol), and GaCl₃ (187 mg, 1.06 mmol) as a mixture of diastereomers (*cis:trans* = 1:1.6) in 300 mg yield (93%). Both diastereomers were partially separated by chromatography according to the general procedure.

The following are data for compound 5f, enriched by the cis-isomer (cis:trans = 2:1). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3008, 2957, 2932, 2873, 2862, 1732 (O=CO), 1603, 1491, 1452, 1437, 1379, 1297, 1273 cm⁻¹. MS (m/z (rel intens, %)): 318 (3, M⁺), 287 (7, M⁺ – OCH₃), 255 (2), 186 (100), 143 (25), 129 (66), 115 (13), 91 (6), 59 (19). HRMS: calcd for C₁₉H₂₆O₄ M + Na 341.1723, M+K 357.1463, found m/z 341.1716, 357.1461. ¹H NMR (CDCl₃, 400.1 MHz for cis-**5f**): δ 0.85–0.98 (m, 3H, CH₃(4')), 1.20–1.36 (m, 2H, CH₂(2')), 1.22–1.43 (m, 2H, $CH_2(3')$), 1.23 (ddd, 1H, syn-H(3), ²J = 12.6 Hz, ${}^{3}J$ = 12.1 and 11.7 Hz), 1.50–1.64 (m, 1H, CH_a(1')), 1.84–1.96 (m, 1H, $CH_b(1')$), 2.05 (dddd, 1H, anti-H(3), ²J = 12.6 Hz, ³J = 5.4 and 2.6 Hz, ⁴J = 2.4 Hz), 2.46-2.57 (m, 1H, H(2)), 2.62 (dd, 1H, anti-H(1), ²J = 15.5 Hz, ³J = 12.0 Hz), 2.77 (ddd, 1H, syn-H(1), ²J = 15.5Hz, ³J = 4.2 Hz, ⁴J = 2.4 Hz), 2.86–2.98 (m, 1H, H(4)), 3.35 (d, 1H, CH, ${}^{3}J = 8.4$ Hz), 3.77 (s, 6H, 2 OMe), 7.05–7.22 (m, 3H, CH(6), C(7) and CH(8)), 7.25–7.29 (m, 1H, CH(5)). $^{13}C{^1H}$ NMR (CDCl₃, 100.6 MHz): δ 14.2 (CH₃), 23.2 (CH₂(3')), 28.4 (CH₂(2')), 34.0 (CH₂(3)), 34.6 (CH₂(1)), 34.8 (CH(2)), 35.7 (CH₂(1')), 38.0 (CH(4)), 52.45 and 52.49 (2OMe), 57.7 (CH), 125.6, 126.2, and 129.1 (CH(6), CH(7) and CH(8)), 127.0 (CH(5)), 136.0 (C(8a)), 139.9 (C(4a)), 168.93 and 169.01 (2COO).

The following are data for compound **5f**, enriched by the *trans*isomer (*cis:trans* = 1:3). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3007, 2956, 2932, 2873, 2861, 1751, 1732 (O=CO), 1491, 1452, 1436, 1379, 1337, 1297, 1272 cm⁻¹. MS (*m*/*z* (rel intens, %)): 318 (2, M⁺), 287 (5, M⁺ – OCH₃), 255 (2), 226 (2), 201 (5), 186 (100), 169 (4), 143 (13), 129 (75), 115 (13), 101 (9), 91 (7), 59 (15). HRMS: calcd for C₁₉H₂₆O₄ M + H 319.1904, M + Na 341.1723, M + K 357.1463, found *m*/*z* 319.1905, 341.1720, 357.1463. ¹H NMR (CDCl₃, 400.1 MHz for trans-4f): δ 0.85–0.98 (m, 3H, CH₃(4')), 1.22–1.43 (m, 2H, CH₂(3')), 1.31–1.47 (m, 2H, CH₂(2')), 1.55–1.67 (m, 2H, CH₂(1')), 1.84–1.93 (m, 2H, CH₂(3)), 2.57 (dd, 1H, syn-H(1), ²J = 15.9 Hz, ³J = 10.8 Hz), 2.64–2.77 (m, 1H, H(2)), 2.74–2.87 (m, 1H, H(4)), 2.88 (ddd, 1H, anti-H(1), ²J = 15.9 Hz, ³J = 4.7 Hz, ⁴J = 1.3 Hz), 3.34 (d, 1H, CH), ³J = 8.9 Hz), 3.77 (s, 6H, 2 OMe), 7.00–7.05 (m, 1H, CH(8)), 7.05–7.20 (m, 3H, CH(5), CH(6) and CH(7)). ¹³C{¹H} NMR (CDCl₃, 100.6 MHz): δ 14.2 (CH₃), 22.8 (CH₂(3')), 30.0 (C(2')), 30.2 (C(2)), 30.6 (C(3))), 33.7 (C(1)), 37.2 (C(1')), 37.7 (C(4)), 52.45 and 52.48 (2OMe), 57.5 (CH), 125.8, 125.9, and 129.0 (C(5), C(6) and C(7)), 129.1 (C(8)), 134.8 (C(8a)), 141.1 (C(4a)), 168.99 and 169.04 (2COO).

2-(1,3-Dimethoxy-1,3-dioxopropan-2-yl)-4,4-diphenyl-1,2,3,4-tetrahydronaphthalene (5g). The title compound was prepared according to the general procedure from cyclopropane 1a (100 mg, 0.43 mmol), 1,1-diphenylethylene (2g) (310 mg, 1.72 mmol) and GaCl₃ (83 mg, 0.47 mmol) in 107 mg yield (61%). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3010, 2954, 1733 (O=CO), 1492, 1455, 1437, 1282, 1244 cm⁻¹. MS (m/z (rel intens, %)): 414 (1, M⁺), 383 (2, M⁺ - OCH₃), 282 (100), 204 (24), 191 (45), 179 (30), 115 (15), 91 (10). HRMS: calcd for C₂₇H₂₆O₄ M + Na 437.1723, found m/z 437.1732. ¹H NMR (CDCl₃, 400.1 MHz): δ 2.35–2.46 (m, 1H, H(2)), 2.48 (dd, 1H, anti-H(1), ${}^{2}J$ = 12.3 Hz, ${}^{3}J$ = 12.0 Hz), 2.65 (ddd, 1H, syn-H(1), ${}^{2}J$ = 12.3 Hz, ${}^{3}J$ = 1.8 Hz, ${}^{4}J$ = 1.8 Hz), 2.81 (dd, 1H, $H_a(3)$, ²J = 16.7 Hz, ³J = 10.4 Hz), 2.94 (ddd, 1H, $H_b(3)$, ²J = 16.7 Hz, ${}^{3}J$ = 6.0 Hz, ${}^{4}J$ = 1.8 Hz), 3.33 (d, 1H, CH, ${}^{3}J$ = 8.1 Hz), 3.68 and 3.70 (both s, $2 \times 3H$, 2 OMe), 6.68 (br d, 1H, H(5), ${}^{3}J = 7.6$ Hz), 6.97– 7.04 (m, 2H, 2 o-H'), 6.98-7.07 (m, 2H, H(6) and H(7)), 7.04-7.09 (m, 2H, 2 o-H"), 7.12–7.17 (m, 1H, H(8)), 7.13–7.21 (m, 2H, p-H"), 7.17-7.25 (m, 2H, 2 m-H"), 7.19-7.26 (m, 2H, p-H'), 7.25-7.33 (m, 2H, 2 m-H'). ¹³C{¹H} NMR (CDCl₂, 100.6 MHz): δ 31.2 (CH(2)), 34.0 (CH₂(1)), 42.5 (CH₂(3)), 52.46 and 52.51 (2 OMe), 54.4 (C(4)), 57.7 (CH), 125.7, 126.3, 126.5, 126.6, 129.4, and 131.7 (CH(5)-CH(8) and 2 p-CH), 127.9, 128.0, 129.3, and 129.6 (2 × 2 o-CH and 2 × 2 m-CH), 135.9, 142.1, 146.0, and 149.4 (C(4a), C(8a) and 2 i-C), 168.7 and 168.8 (2COO).

(2RS,4SR)- and (2RS,4RS)-2-(1,3-dimethoxy-1,3-dioxopropan-2-yl)-4-methyl-4-phenyl-1,2,3,4-tetrahydronaphthalene (5h). The title compound was prepared according to the general procedure from cyclopropane 1a (200 mg, 0.85 mmol), α methylstyrene (2h) (296 mg, 2.55 mmol), and GaCl₃ (157 mg, 0.89 mmol) as a mixture of diastereomers (2RS,4SR:2RS,4RS = 1.5:1) in 134 mg total yield (45%). Both diastereomers were partially separated by chromatography according to the general procedure.

The following are data for compound (2RS,4SR)-5h (major diastereomer, ~85% purity). colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3008, 2956, 2931, 2871, 1750, 1732 (O=CO), 1599, 1494, 1437, 1377, 1341, 1274 cm⁻¹. MS (m/z (rel intens, %)): 352 (4, M⁺), 338 (19), 323 (19), 303 (3), 235 (3), 220 (93), 205 (100), 191 (12), 178 (16), 143 (49), 129 (34), 115 (33), 105 (39), 91 (77), 77 (11), 59 (13). HRMS: calcd for C₂₂H₂₄O₄ M + H 353.1747, M + Na 375.1567, M + K 391.1306, found: *m*/*z* 353.1744, 375.1562, 391.1304. ¹H NMR (CDCl₃, 400.1 MHz): δ 1.74 (s, 3H, Me), 1.76-1.94 (m, 2H, CH₂(3)), 2.59–2.95 (m, 3H, H(2) and CH₂(1)), 3.32 (d, 1H, CH, ³J = 8.5 Hz), 3.73 and 3.78 (both s, 2 \times 3H, 2 OMe), 6.75 (br d, 1H, H(5), ${}^{3}J = 7.7$ Hz), 6.97–7.30 (m, 8H, 2Ar except H(5)). ${}^{13}C{}^{1}H{}$ NMR (CDCl₃, 100.6 MHz): δ 29.2 (Me), 32.3 (CH(2)), 34.7 (CH₂(1)), 44.4 (C(4)), 46.6 (CH₂(3)), 52.51 and 52.57 (2 OMe), 57.5 (CH), 125.85, 125.89, 126.4, and 129.0 (CH(6), CH(7), CH(8) and p-CH), 127.4 and 128.2 (2 o-CH and 2 m-CH), 129.7 (CH(5)), 134.9 (C(8a)), 144.9 (C(4a)), 151.4 (i-C), 168.75 and 168.82 (2COO).

The following are data for ompound (2*RS*,4*RS*)-**5h** (minor diastereomer, ~95% purity). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3007, 2955, 2935, 2875, 2847, 1732 (O=CO), 1597, 1493, 1437, 1376, 1341, 1293, 1253 cm⁻¹. MS (*m*/*z* (rel intens, %)): 352 (1, M⁺), 303 (3), 220 (97), 205 (100), 192 (10), 178 (15), 143 (18), 129 (21), 115 (11), 105 (19), 91 (23), 77 (6), 59 (6). HRMS: calcd for C₂₂H₂₄O₄ M + Na 375.1567, M + K 391.1306, found *m*/*z* 375.1562, 391.1319. ¹H NMR (CDCl₃, 400.1 MHz): δ 1.74 (s, 3H, Me), 1.77

(dd, 1H, *syn*-H(3), ${}^{2}J$ = 12.8 Hz, ${}^{3}J$ = 11.7 Hz), 2.13 (ddd, 1H, *anti*-H(3), ${}^{2}J$ = 12.8 Hz, ${}^{3}J$ = 2.4 Hz, ${}^{4}J$ = 2.0 Hz), 2.26–2.37 (m, 1H, H(2)), 2.70 (dd, 1H, *syn*-H(1), ${}^{2}J$ = 16.3 Hz, ${}^{3}J$ = 11.6 Hz), 2.90 (ddd, 1H, *anti*-H(1), ${}^{2}J$ = 16.3 Hz, ${}^{3}J$ = 2.0 Hz), 3.26 (d, 1H, CH, ${}^{3}J$ = 8.0 Hz), 3.63 and 3.67 (both s, 2 × 3H, 2 OMe), 6.94–6.99 (m, 2H, 2 *o*-H), 7.10–7.16 (m, 1H, *p*-H), 7.11–7.17 (m, 1H, H(8)), 7.15–7.27 (m, 3H, H(5)–H(7)), 7.18–7.25 (m, 2H, 2 *m*-H). ${}^{13}C{}^{1}H{}$ NMR (CDCl₃, 100.6 MHz): δ 30.8 (CH(2)), 31.1 (Me), 34.2 (CH₂(1)), 43.7 (C(4)), 44.6 (CH₂(3)), 52.38 and 52.43 (2 OMe), 57.3 (CH), 125.9 (*p*-CH), 126.4, 126.5, and 128.5 (CH(5), C(6) and CH(7)), 127.3 (2 *o*-CH), 128.0 (2 *m*-CH), 129.4 (CH(8)), 136.0 (C(8a)), 142.5 (C(4a)), 150.1 (*i*-C), 168.7 and 168.9 (2COO).

2-(1,3-Dimethoxy-1,3-dioxopropan-2-yl)-4,4-dimethyl-1,2,3,4-tetrahydronaphthalene (5i). The title compound was prepared according to the general procedure from cyclopropane 1a (200 mg, 0.85 mmol), isobutylene (2i) (57 mg, 1.02 mmol), and GaCl₃ (150 mg, 0.85 mmol) in 213 mg yield (86%). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3011, 2957, 2930, 2868, 1732 (C=O), 1602, 1490, 1436, 1366, 1302, 1292 cm⁻¹. MS (m/z (rel intens, %)): 262 (75), 247 (21), 205 (11), 158 (76), 143 (100), 128 (23), 115 (12), 91 (8), 59 (10). HRMS: calcd for C₁₇H₂₂O₄ M + H 291.1591, M + Na 313.1410, M + K 329.1150, found m/z 291.1604, 313.1415, 329.1152. ¹H NMR (CDCl₃, 400.1 MHz): δ 1.29 and 1.33 (both s, 2 × 3H, 2 Me), 1.47 $(dd, 1H, H_a(3), {}^{2}J = 12.8 Hz, {}^{3}J = 12.0 Hz), 1.69 (ddd, 1H, H_b(3), {}^{2}J =$ 12.8 Hz, ${}^{3}J = 2.3$ Hz, ${}^{4}J = 2.6$ Hz), 2.63–2.74 (m, 1H, H(2)), 2.61 (dd, 1H, anti-H(1), ²J = 14.6 Hz, ³J = 12.2 Hz), 2.82 (ddd, 1H, syn-H(1), ²) = 14.6 Hz, ${}^{3}J$ = 3.6 Hz, ${}^{4}J$ = 2.6 Hz), 3.34 (d, 1H, CH, ${}^{3}J$ = 8.4 Hz), 3.77 and 3.78 (both s, 2 × 3H, 2 OMe), 7.02 (br d, 1H, H(5), ${}^{3}J = 7.5$ Hz), 7.07 (ddd, 1H, H(6), ${}^{3}J$ = 7.5 and 7.4 Hz, ${}^{4}J$ = 1.3 Hz), 7.15 (br dd, 1H, H(7), ${}^{3}J$ = 7.4 and 7.6 Hz), 7.31 (br dd, 1H, H(8), ${}^{3}J$ = 7.6 Hz, ${}^{4}J$ = 1.3 Hz). ${}^{13}C{}^{1}H$ NMR (CDCl₃, 100.6 MHz): δ 31.71 and 31.73 (2 Me), 32.3 (CH(2)), 35.0 (CH₂(1)), 35.1 (C(4)), 43.7 (CH₂(3)), 52.55 and 52.59 (2 OMe), 57.7 (CH), 125.7 (CH(6)), 126.4 (CH(7)), 126.6 (CH(8)), 129.2 (CH(5)), 134.4 (C(8a)), 145.0 (C(4a)), 169.01 and 169.03 (2COO).

2-(1,3-Dimethoxy-1,3-dioxopropan-2-yl)-3,4-diphenyl-1,2,3,4-tetrahydronaphthalene (5j). The title compound was prepared according to the general procedure from cyclopropane 1a (200 mg, 0.85 mmol), trans-stilbene (2j) (612 mg, 3.40 mmol), and GaCl₃ (158 mg, 0.90 mmol) as a single diastereomer in 285 mg yield (81%). Colorless thick oil. IR (CHCl3): v 3020, 2955, 1746, 1730 (O=CO), 1493, 1453, 1437, 1224, 1208 cm⁻¹. MS (m/z (rel intens, %)): 414 (2, M⁺), 383 (3, M⁺ - OCH₃), 282 (100), 215 (4), 204 (13), 191 (40), 179 (31), 165 (10), 115 (7), 91 (8). HRMS: calcd for C₂₇H₂₆O₄ M + H 415.1904, M + Na 437.1723, found: *m*/*z* 415.1914, 437.1733. ¹H NMR (CDCl₃, 400.1 MHz): δ 2.97 (dddd, 1H, H(2), ³J = 11.2, 11.0, 3.8, and 3.0 Hz), 3.04 (dd, 1H, anti-H(1), ${}^{2}J$ = 16.0 Hz, ${}^{3}J$ = 3.0 Hz), 3.19 (dd, 1H, H(3), ${}^{3}J$ = 11.2 and 10.8 Hz), 3.35 (d, 1H, CH, ${}^{3}J = 3.8$ Hz), 3.48 (dd, 1H, syn-H(1), ${}^{2}J = 16.0$ Hz, ${}^{3}J = 11.0$ Hz), 3.62 and 3.68 (both s, $2 \times 3H$, 2 OMe), 4.22 (d, 1H, H(4), ${}^{3}J = 10.8$ Hz), 6.72 (br d, 1H, H(5), ${}^{3}J$ = 7.7 Hz), 6.76–6.83 (m, 2H, 2 o-H"), 6.90-6.96 (m, 2H, o-H'), 6.99-7.04 (m, 1H, H(6)), 7.03-7.11 (m, 3H, 2 m-H" and p-H"), 7.10-7.15 (m, 1H, H(7)), 7.13-7.20 (m, 2H, 2 m-H'), 7.15-7.19 (m, 1H, H(8)), 7.19-7.16 (m, 2H, p-H'). $^{13}C{^{1}H}$ NMR (CDCl₃, 100.6 MHz): δ 32.3 (CH₂(1)), 40.0 (CH(2)), 51.9 and 52.5 (2 OMe), 52.9 (CH), 53.2 (CH(3)), 55.2 (C(4)), 126.1 (together CH(6), CH(7) and p-CH"), 126.8 (p-C'), 128.0 (2 m-CH"), 128.47 and 128.52 (2 o-CH' and 2 m-CH'), 128.7 (CH(8)), 129.4 (2 o-CH"), 129.9 (CH(5)), 136.1 (C(8a)), 139.5 (C(4a)), 141.7 (i-C'), 145.1 (i-C"), 168.7 and 169.9 (2COO).

(2RS,3SR,4SR)- and (2RS,3RS,4RS)-2-(1,3-Dimethoxy-1,3-dioxopropan-2-yl)-3-methyl-4-phenyl-1,2,3,4-tetrahydronaphthalene (5k). The title compound was prepared according to the general procedure from cyclopropane 1a (250 mg, 1.07 mmol), β methylstyrene (2k) (505 mg, 4.28 mmol), and GaCl₃ (198 mg, 1.12 mmol) as a mixture of diastereomers (2RS,3SR,4SR:2RS,3RS,4RS = 1.2:1) in 335 mg total yield (89%). Both diastereomers were fully separated by chromatography according to the general procedure.

The following are data for compound $(2RS_3SR_4SR)$ -**5k** (major diastereomer). Colorless powder. Mp: 98–100 °C. IR (CHCl₃): $\tilde{\nu}$

3007, 2956, 2931, 2875, 2852, 1731 (C=O), 1600, 1493, 1452, 1437, 1380, 1316, 1285, 1251 cm⁻¹. MS (m/z (rel intens, %)): 352 (1, M⁺), 338 (2), 321 (5), 220 (100), 205 (86), 191 (20), 179 (46), 165 (19), 142 (20), 129 (47), 105 (18), 91 (62), 93 (12), 59 (10). HRMS: calcd for C₂₂H₂₄O₄ M + Na 375.1567, found m/z 375.1562. ¹H NMR $(CDCl_3, 400.1 \text{ MHz}): \delta 0.92 \text{ (d, 3H, Me, }^3J = 6.5 \text{ Hz}), 2.04 \text{ (ddq, 1H, }$ H(3), ${}^{3}J = 10.3$, 9.8, and 6.5 Hz), 2.46 (dddd, 1H, H(2), ${}^{3}J = 10.8$, 9.8, 5.0, and 4.5 Hz), 2.88 (dd, 1H, anti-H(1), ${}^{2}J = 16.1$ Hz, ${}^{3}J = 4.5$ Hz), 3.23 (dd, 1H, syn-H(1), ²J = 16.1 Hz, ³J = 10.8 Hz), 3.61 (d, 1H, H(4), ${}^{3}J = 10.3$ Hz), 3.73 and 3.76 (both s, 2 × 3H, 2 OMe), 3.76 (d, 1H, CH, ${}^{3}J = 5.0$ Hz), 6.63 (br d, 1H, H(5), ${}^{3}J = 7.8$ Hz), 6.94–7.00 (m. 1H, H(6)), 7.03-7.10 (m, 2H, H(7) and H(8)), 7.09-7.14 (m, 2H, 2 *o*-H), 7.19–7.25 (m, 1H, *p*-H), 7.25–7.32 (m, 2H, 2 *m*-H). ¹³C{¹H} NMR (CDCl₃, 100.6 MHz): δ 17.7 (Me), 32.2 (CH₂(1)), 39.8 (CH(2)), 41.0 (CH(3)), 52.2 and 52.5 (2 OMe), 53.5 (CH), 54.9 (CH(4)), 125.9 (CH(7)), 126.0 (CH(6)), 126.4 (p-CH), 128.5 (CH(8) and 2 m-CH), 129.66 (CH(5)), 129.68 (2 o-CH), 136.1 (C(8a)), 139.8 (C(4a)), 145.6 (i-C), 168.9 and 169.8 (2COO).

The following are data for compound (2RS,3RS,4RS)-5k (minor diastereomer). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3007, 2956, 2885, 2846, 1732 (C=O), 1600, 1493, 1448, 1384, 1332, 1279, 1262 cm⁻¹ MS (*m*/*z* (rel intens, %)): 352 (1, M⁺), 321 (1), 220 (100), 205 (39), 191 (9), 179 (13), 165 (7), 129 (14), 105 (10), 91 (19), 59 (4). HRMS: calcd for C₂₂H₂₄O₄ M + Na 375.1567, M + K 391.1306, found m/z 375.1556, 391.1298. ¹H NMR (CDCl₃, 400.1 MHz): δ 1.01 (d, 3H, Me, ³J = 7.0 Hz), 2.09 (ddq, 1H, H(3), ³J = 7.0, 2.6, and 2.4 Hz), 2.60 (dd, 1H, H(1)-a, ${}^{2}J$ = 15.8 Hz, ${}^{3}J$ = 11.4 Hz), 2.67 (dddd, 1H, H(2), ${}^{3}J = 11.4$, 10.5, 4.4, and 2.6 Hz), 2.91 (dd, 1H, H(1)-b, ${}^{2}J = 15.8$ Hz, ${}^{3}J$ = 4.4 Hz), 3.39 (d, 1H, CH, ${}^{3}J$ = 10.5 Hz), 3.53 and 3.70 (both s, 2 × 3H, 2 OMe), 4.02 (d, 1H, H(4), ${}^{3}J$ = 2.4 Hz), 6.87–6.94 (m, 2H, 2 o-H), 6.97 (br d, 1H, H(5), ${}^{3}J$ = 7.5 Hz), 7.07–7.19 (m, 3H, H(7), H(8) and p-H), 7.18-7.27 (m, 1H, 2 m-H). ¹³C{¹H} NMR (CDCl₃, 100.6 MHz): δ 14.2 (Me), 29.2 (CH₂(1)), 32.4 (CH(2)), 37.5 (CH(3)), 52.26 and 52.45 (2 OMe), 52.29 (CH), 55.4 (CH(4)), 126.0, 126.2, and 126.3 (CH(6), CH(7) and p-CH), 128.1 (2 m-CH), 128.7 (2 o-CH), 128.9 (CH(8)), 131.4 (CH(5)), 135.4 (C(8a)), 135.9 (C(4a)), 146.4 (i-C), 168.4 and 169.0 (2COO).

(4bSR,8aSR,9RS)-9-(1,3-Dimethoxy-1,3-dioxopropan-2-yl)-4b-phenyl-4b,5,6,7,8,8a,9,10-octahydrophenanthrene (5l). The title compound was prepared according to the general procedure from cyclopropane 1a (100 mg, 0.43 mmol), phenylcyclohexene (2l) (344 mg, 2.15 mmol), and GaCl₃ (79 mg, 0.45 mmol) as a single diastereomer in 90 mg yield (53%). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3011, 2936, 2857, 1731 (O=CO), 1605, 1493, 1478, 1450, 1436, 1311, 1266 cm⁻¹. MS (m/z (rel intens, %)): 392 (2, M⁺), 361 (1, M⁺ - OMe), 332 (3, M⁺ - HCO₂Me), 302 (1), 274 (4), 260 (100), 217 (28), 203 (21), 169 (19), 141 (30), 115 (34), 100 (25), 91 (67), 59 (78). HRMS: calcd for C₂₅H₂₈O₄ M + H 393.2060, M + Na 415.1880, M + K 431.1619, found *m/z* 393.2056, 415.1873, 431.1621. ¹H NMR $(CDCl_3, 400.1 \text{ MHz}): \delta 1.06 \text{ (dddd, 1H, CH}_3(8), {}^2J = 13.2 \text{ Hz}, {}^3J =$ 10.7, 10.1, and 3.2 Hz), 1.32-1.45 and 1.52-1.66 (both m, 2 × 1H, $CH_2(7)$), 1.50 (br dddd, 1H, $CH_b(8)$, ²J = 13.2 Hz, ³J = 4.7, 3.9, and 3.5 Hz), 1.56–1.70 (m, 2H, CH₂(6)), 1.87 (ddd, 1H, H₂(5), $^{2}J = 14.7$ Hz, ${}^{3}J = 9.8$ and 5.1 Hz), 2.15 (br dd, 1H, H_a(10), ${}^{2}J = 14.9$ Hz, ${}^{3}J =$ 10.3 Hz), 2.31 (br ddd, 1H, $H_b(5)$, ²*J* = 14.7 Hz, ³*J* = 4.3 and 4.1 Hz), 2.39 (dddd, 1H, H(9), ³*J* = 10.3, 9.8, 6.6, and 3.9 Hz), 2.46 (ddd, 1H, H(8a), ³*J* = 10.1, 3.9, and 3.9 Hz), 2.67 (dd, 1H, $H_b(10)$, ²*J* = 14.9 Hz, ${}^{3}J = 6.6$ Hz), 3.24 (d, 1H, H(2'), ${}^{3}J = 9.8$ Hz), 3.67 and 3.81 (both s, 2 \times 3H, 2 OMe), 7.02–7.28 (m, 9H, 2 Ar). $^{13}\mathrm{C}\{^{1}\mathrm{H}\}$ NMR (CDCl₃, 100.6 MHz): δ 22.9 (CH₂(6)), 25.5 (br, CH₂(7)), 31.8 (br, CH₂(8)), 32.2 (CH₂(10)), 38.7 (br, CH₂(5)), 39.5 (br, CH(9)), 43.2 (CH(8a)), 48.6 (C(4b)), 52.5 and 52.6 (2 OMe), 57.2 (br, CH(2')), 126.1 (CH, Ar), 126.3 (2CH, Ar), 127.3 (2CH, Ar), 128.5 (3CH, Ar), 128.9 (CH, Ar), 136.9 (C(10a)), 142.2 (br) and 148.7 (C(4a) and i-C), 169.0 and 169.6 (2COO)

(4bSR,8aSR,9RS)-9-(1,3-Dimethoxy-1,3-dioxopropan-2-yl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene (5m). The title compound was prepared according to the general procedure from cyclopropane 1a (100 mg, 0.43 mmol), cyclohexene (2m) (212 mg, 2.58 mmol), and GaCl₃ (79 mg, 0.45 mmol) as a single diastereomer

in 57 mg yield (42%). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3011, 2953, 2934, 2858, 1734 (O=CO), 1602, 1494, 1450, 1436, 1372, 1305, 1289, 1255 cm⁻¹. MS (m/z (rel intens, %)): 316 (1, M⁺), 285 (1, M⁺) - OCH₃), 235 (2), 224 (2), 184 (100), 169 (6), 155 (8), 141 (47), 133 (22), 115 (19), 91 (13), 59 (11). HRMS: calcd for C₁₀H₂₄O₄ M + Na 339.1567, found m/z 339.1565. ¹H NMR (CDCl₃, 400.1 MHz): δ 1.07 (dt, 1H, $J \approx 12.7$ and 3.6 Hz), 1.14 (tt, 1H, $J \approx 12.8$ and 3.2 Hz), 1.21-1.29 (m, 1H), 1.40-1.54 (m, 2H), 1.61-1.71 (m, 1H), 1.62-1.69 (m, 1H), 1.82-1.91 (m, 1H), 2.43-2.52 (m, 1H) [for all H from $CH_2(5)-CH_2(8)$ and CH(8a)], 2.61 (dd, 1H, $H_a(10)$, ²J = 14.9 Hz, ³J = 12.4 Hz), 2.69 (dddd, 1H, H(9), ${}^{3}I$ = 12.4, 10.6, 4.2, and 2.4 Hz), 2.78 (dd, 1H, H_b(10), ${}^{2}J$ = 14.9 Hz, ${}^{3}J$ = 4.2 Hz), 3.05-3.12 (m, 1H, H(4b)), 3.48 (d, 1H, H(2'), ${}^{3}J$ = 10.6 Hz), 3.77 and 3.78 (both s, 2 × 3H, 2 OMe), 7.04 (br d, 1H, H(1) or H(4), ${}^{3}J \approx 7.5$ Hz), 7.11 (ddt, 1H, H(2) or H(3), ${}^{3}J \approx 7.3$ Hz, ${}^{4.5}J \approx 1.3$ and 1.0 Hz), 7.17 (dt, 1H, H(2) or H(3), ${}^{3}J \approx 7.5$ Hz, ${}^{4.5}J \approx 1.3$ Hz), 7.33 (br d, 1H, H(1) or H(4), ${}^{3}I \approx 7.8$ Hz). ${}^{13}C{}^{1}H{}$ NMR (CDCl₂, 100.6 MHz): δ 20.9, 21.1, 26.2, 29.3, and 30.5 (CH₂(5)-CH₂(8) and CH₂(10)), 37.9, 38.9, and 39.2 (CH(4b), CH(8a) and CH(9)), 52.58 and 52.62 (2 OMe), 55.4 (CH), 125.6, 126.4, 126.5, and 129.2 (CH(1)-CH(4)), 135.6 and 137.5 (C(4a) and C(10a)), 169.0 and 169.1 (2 COO).

(6R5,6aSR,11bRS)- and (6SR,6aSR,11bRS)-6-(1,3-Dimethoxy-1,3-dioxopropan-2-yl)-6,6a,7,11b-tetrahydro-5H-benzo[c]fluorene (5n). The title compound was prepared according to the general procedure from cyclopropane 1a (100 mg, 0.43 mmol), indene (2n) (299 mg, 2.58 mmol), and GaCl₃ (79 mg, 0.45 mmol) as a mixture of diastereomers (6RS,6aSR,11bRS:6RS,6aSR,11bSR \approx 2.5:1) in 80 mg total yield with 70–80% purity (40%). A crude mixture of diastereomers was purified and separated by PTLC according to the general procedure to give single diastereomers with 90–95% purity, but the quantity of substances was small due to its very poor separation during chromatography. Compound **5n** has a low stability in solution and very easily oxidizes in air.

The following are data for compound (6RS,6aSR,11bRS)-**5n** (major diastereomer). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 2956, 2929, 2853, 1734 (O=CO), 1602, 1519, 1457, 1437, 1284 cm⁻¹. MS (*m*/*z* (rel intens, %)): 350 (2, M⁺), 319 (4, M⁺ – OCH₃), 287 (1), 259 (2), 231 (5), 218 (100), 202 (20), 189 (5), 178 (5), 133 (5), 115 (6), 91 (2), 59 (4). HRMS: calcd for C₂₂H₂₂O₄ M + H 351.1591, M + Na 373.1410, found *m*/*z* 351.1592, 373.1416. ¹H NMR (CDCl₃, 400.1 MHz): δ 2.55–2.62 (m, 1H, H(6)), 2.71 (dd, 1H, ³J = 15.8 Hz, ³J = 7.3 Hz), 2.78–2.93 (m, 3H) and 3.14 (dd, 1H, ³J = 15.6 Hz, ³J = 7.6 Hz) (H(6a), CH₂(5) and CH₂(7)), 3.51 (d, 1H, CH, ³J = 8.3 Hz), 3.72 and 3.74 (both s, 2 × 3H, 2 OMe), 4.35 (d, 1H, H(11b), ³J = 7.7 Hz), 7.03–7.08 (m, 1H), 7.10–7.23 (m, 5H) and 7.29–7.36 (m, 2H) (2Ar).

The following are data for compound (6*RS*,6a*S*R,11b*S*R)-**5n** (minor diastereomer). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3008, 2958, 2925, 1734 (O=CO), 1601, 1520, 1457, 1437, 1289 cm⁻¹. MS (*m*/*z* (rel intens, %)): 319 (2, M⁺ – OCH₃), 286 (3), 271 (3), 260 (16), 218 (100), 203 (22), 178 (9), 165 (7), 141 (7), 133 (14), 115 (24), 91 (22), 59 (35). HRMS: calcd for C₂₂H₂₂O₄ M + H 351.1591, M + Na 373.1410, found *m*/*z* 351.1586, 373.1410. ¹H NMR (CDCl₃, 400.1 MHz): δ 2.67–3.05 (m, 6H, H(6), H(6a), CH₂(5) and CH₂(7)), 3.50 (d, 1H, CH, ³*J* = 10.8 Hz), 3.76 and 3.81 (both s, 2 × 3H, 2 OMe), 4.46 (d, 1H, H(11b), ³*J* = 7.6 Hz), 7.01 (br d, 1H, ³*J* = 6.8 Hz), 7.06 (br dd, 1H, ³*J* ≈ 6.7 and 6.9 Hz), 7.09–7.21 (m, 4H), 7.48 (br d, 1H, ³*J* = 7.8 Hz), 7.54 (br d, 1H, ³*J* = 6.9 Hz) (2Ar).

(6*RS*,6a*SR*,12b*RS*)-6-(1,3-Dimethoxy-1,3-dioxopropan-2-yl)-5,6,6a,7,8,12b-hexahydrobenzo[c]phenanthrene (5o). The title compound was prepared according to the general procedure from cyclopropane 1a (150 mg, 0.64 mmol), dihydronaphthalene (2o) (250 mg, 1.92 mmol), and GaCl₃ (118 mg, 0.67 mmol) as a single diastereomer in 102 mg yield (44%). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3032, 3011, 2955, 2929, 1732 (O=CO), 1492, 1451, 1436, 1243, 1159 cm⁻¹. MS (*m*/*z* (rel intens, %)): 364 (1, M⁺), 333 (2, M⁺ – OCH₃), 232 (100), 217 (22), 204 (12), 191 (6), 178 (8), 141 (9), 133 (20), 117 (25), 91(9), 69 (18), 59 (15). HRMS: calcd for C₂₃H₂₄O₄ M + Na 387.1567, found *m*/*z* 387.1569. ¹H NMR (CDCl₃, 400.1 MHz): δ 1.26–1.39 (m, 1H, anti-H(7)), 1.65–1.74 (m, 1H, syn-H(7)), 2.17– 2.28 (m, 2H, H(6) and H(6a)), 2.69–2.88 (m, 4H, CH₂(5) and CH₂(8)), 3.62 (d, 1H, CH, ${}^{3}J$ = 7.6 Hz), 3.74 and 3.77 (both s, 2 × 3H, 2 OMe), 4.03 (d, 1H, H(12b), ${}^{3}J$ = 4.9 Hz), 6.71 (br d, 1H, H(1), ${}^{3}J$ = 7.4 Hz), 7.05–7.12 (m, 1H, H(2)), 7.11–7.16 (m, 2H, H(3) and H(4)), 7.10–7.23 (m, 4H, H(9)–H(12)). ${}^{13}C{}^{1}H$ NMR (CDCl₃, 100.6 MHz): δ 27.7 (CH₂(7)), 29.1 (CH₂(8)), 31.7 (CH₂(5)), 37.1 (CH(6a)), 40.1 (CH(6)), 42.0 (CH(12b)), 52.5 (2 OMe), 56.1 (CH), 125.4 (CH(10)), 126.1 (CH(3)), 126.2 (CH(2)), 126.5 (CH(11)), 127.5 (CH(4)), 127.8 (CH(1)), 129.2 (CH(9)), 131.1 (CH(12)), 136.56 and 136.58 (C(4a) and C(8a)), 137.2 (C(12a)), 140.7 (C(12c)), 169.13 and 169.16 (2 COO).

(1S*,2S*,3R*)-1,3-Bis(1,3-dimethoxy-1,3-dioxopropan-2-yl)-2-phenyl-1,2,3,4-tetrahydronaphthalene (5p). The title compound was prepared according to the general procedure from cyclopropane 1a (200 mg, 0.85 mmol), styrylmalonate 2p (200 mg, 0.85 mmol), and GaCl₃ (165 mg, 0.94 mmol) as a single diastereomer in 332 mg yield (83%). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3020, 2955, 2921, 1733 br (O=CO), 1602, 1519, 1494, 1454, 1437 cm⁻¹. ¹H NMR (CDCl₃, 400.1 MHz): δ 2.54 (dddd, 1H, H(3), ³J = 12.5, 10.4, 4.2, and 3.8 Hz), 2.88 (dd, 1H, anti-H(4), ${}^{2}J = 15.0$, ${}^{3}J = 3.8$ Hz), 3.03 (dd, 1H, syn-H(4), ${}^{2}J$ = 15.0, ${}^{3}J$ = 12.5 Hz), 3.28 and 3.71 (both s, 2 × 3H, 2OMe at C(2'), 3.32 (dd, 1H, H(2), ${}^{3}J = 10.4$ and 4.9 Hz), 3.33 (d, 1H, CH, ${}^{3}J$ = 4.2 Hz), 3.59 and 3.69 (both s, 2 × 3H, 2OMe), 3.78 $(d, 1H, H(2'), {}^{3}J = 7.6 Hz), 3.84 (dd, 1H, H(1), {}^{3}J = 7.6 and 4.9 Hz),$ 7.09 (m, 2H, 2 o-CH), 7.13–7.22 (m, 5H, H(5), H(6), H(7), H(8) and o-CH), 7.26 (m, 2H, 2 m-CH). ¹³C{¹H} NMR (CDCl₃, 100.6 MHz): δ 31.9 (CH₂(4)), 43.2 (CH(3)), 47.1 (CH(2)), 47.4 (CH(1)), 52.0 and 52.2 (2OMe at C(2')), 52.3 and 52.4 (2OMe), 53.6 (CH), 57.1 (CH(2')), 126.6, 127.0, 127.1, 128.5, and 128.7 (p-CH, CH(5), CH(6), CH(7) and CH(8)), 128.4 (2 o-CH), 128.7 (2 m-CH), 135.6 (C(8a)), 138.7 (C(4a)), 144.6 (i-C), 168.2 and 168.7 (2COO at C(2')), 168.9 and 169.2 (2COO). MS (*m*/*z* (rel intens, %)): 468 (1, M⁺), 437 (2, M⁺ - OCH₃), 376 (1), 336 (18), 317 (3), 305 (7), 276 (4), 217 (6), 204 (100), 133 (7), 115 (11), 91 (7), 69 (4), 59 (11). HRMS: calcd for C₂₆H₂₈O₈ M + H 469.1857, M + Na 491.1676, found m/z 469.1848, 491.1669.

(1S*,2S*,3R*)-1,3-Bis(1,3-dimethoxy-1,3-dioxopropan-2-yl)-2-(4-fluorophenyl)-1,2,3,4-tetrahydronaphthalene (5q). The title compound was prepared according to the general procedure from cyclopropane 1a (93 mg, 0.40 mmol), styrylmalonate 2q (100 mg, 0.40 mmol), and \mbox{GaCl}_3 (74 mg, 0.42 mmol) as a single diastereomer in 146 mg yield (76%). Colorless thick oil. IR (CHCl₃): ν̃ 3020, 2955, 2919, 1733 br (O=CO), 1658, 1644, 1512, 1435, 1423 cm⁻¹. ¹H NMR (CDCl₃, 400.1 MHz): δ 2.49 (dddd, 1H, H(3), ³J = 12.8, 10.5, 4.3, and 3.9 Hz), 2.87 (dd, 1H, anti-H(4), ${}^{2}J = 15.0$, ${}^{3}J = 3.9$ Hz), 3.00 (dd, 1H, syn-H(4), ${}^{2}J = 15.0$, ${}^{3}J = 12.8$ Hz), 3.30–3.38 (m, 2H, CH and H(2)), 3.30, 3.61, 3.70, and 3.71 (all s, 4 × 3H, 4OMe), 3.72-3.81 (m, 2H, H(1) and H(2')), 6.95 (m, 2H, 2 *m*-CH, ${}^{3}J_{HF} = 8.8$ Hz), 7.05 (m, 2H, 2 o-CH, ${}^{4}J_{\rm HF}$ = 5.3 Hz), 7.05–7.30 (m, 4H, H(5)– H(8)). ${}^{13}C{}^{1}H$ NMR (CDCl₃, 100.6 MHz): δ 32.0 (CH₂(4)), 43.4 (CH(3)), 46.2 (CH(2)), 47.6 (CH(1)), 52.0, 52.3, 52.4, and 52.5 (4OMe), 53.6 (CH), 57.0 (CH(2')), 115.5 (d, 2 m-CH, ${}^{2}J_{CF} = 21.2$ Hz), 126.7, 127.2, 128.5, and 128.8 (CH(5)-CH(8)), 129.8 (d, 2 o-CH, ${}^{3}J_{CF} = 7.8$ Hz), 135.3 (C(8a)), 138.6 (C(4a)), 140.6 (d, *i*-C, ${}^{4}J_{CF}$ = 3.1 Hz), 161.8 (d, p-CF, ${}^{1}J_{CF}$ = 245.5 Hz), 168.2, 168.7, 168.8, and 169.1 (4COO). ¹⁹F NMR (CDCl₃, 282.4 MHz): δ –116.6 (tt, 1F, p-CF, ${}^{3}J_{HF} = 8.8$, ${}^{4}J_{HF} = 5.3$ Hz). MS (m/z (rel intens, %)): 486 (2, M⁺), $455(4, M^{+} - OCH_{3}), 423(2), 394(1), 354(14), 323(7), 294(12),$ 263 (12), 233 (41), 223 (100), 204 (95), 175 (17), 149 (12), 133 (85), 115 (64), 100 (45), 91 (21), 69 (53), 59 (100). HRMS: calcd for C₂₆H₂₇FO₈ M + H 487.1763, M + Na 509.1582, M + K 525.1322, found m/z 487.1762, 509.1582, 525.1320.

(1*S**,2*S**,3*R**)-1,3-Bis(1,3-dimethoxy-1,3-dioxopropan-2-yl)-7-fluoro-2-phenyl-1,2,3,4-tetrahydronaphthalene (5r). The title compound was prepared according to the general procedure from cyclopropane 1b (80 mg, 0.32 mmol), styrylmalonate 2p (74 mg, 0.32 mmol), and GaCl₃ (59 mg, 0.22 mmol) as a single diastereomer in 78 mg yield (51%). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3020, 2974, 2955, 2920, 1734 br (O=CO), 1642, 1616, 1511, 1501, 1454, 1437 cm⁻¹. ¹H NMR (CDCl₃, 300.1 MHz): δ 2.52 (dddd, 1H, H(3), ³*J* = 12.6,

10.6, 4.3, and 3.9 Hz), 2.87 (dd, 1H, anti-H(4), ${}^{2}J$ = 14.9, ${}^{3}J$ = 4.3 Hz), 2.96 (dd, 1H, *syn*-H(4), ${}^{2}J$ = 14.9, ${}^{3}J$ = 12.6 Hz), 3.26–3.38 (m, 2H, CH and H(2)), 3.33, 3.60, 3.70, and 3.71 (all s, 4 × 3H, 4OMe), 3.74–3.87 (m, 2H, H(1) and H(2')), 6.85–6.96 (m, 2H, H(6) and H(8)), 7.03–7.33 (m, 6H, H(5) and Ph). ${}^{13}C{}^{1H}$ NMR (CDCl₃, 100.6 MHz): δ 31.4 (CH₂(4)), 43.1 (CH(3)), 46.9 (CH(2)), 47.4 (CH(1)), 52.2, 52.3, 52.5, and 52.7 (4OMe), 53.5 (CH), 56.8 (CH(2')), 114.0 (d, CH(6) or CH(8), ${}^{2}J_{CF}$ = 21.2 Hz), 115.4 (d, CH(6) or CH(8), ${}^{2}J_{CF}$ = 21.9 Hz), 127.3 (*p*-CH), 128.5 and 118.9 (2 *o*-CH and 2 *m*-CH), 129.9 (d, CH(5), ${}^{3}J_{CF}$ = 7.9 Hz), 134.4 (d, C(4a), ${}^{4}J_{CF}$ = 2.5 Hz), 137.7 (d, C(8a), ${}^{3}J_{CF}$ = 7.0 Hz), 144.2 (*i*-C), 161.6 (d, C(7), ${}^{1}J_{CF}$ = 244.1 Hz), 168.1, 168.7, 168.8, and 169.3 (4COO). 19 F NMR (CDCl₃, 282.4 MHz): δ –117.0 (dddt, 1F, CF(7), ${}^{3}J_{HF} \approx 8.9$ and 8.6, ${}^{4}J_{HF} \approx 5.6$, ${}^{6}J_{HF} \approx 1$ Hz). HRMS: calcd for C₂₆H₂₇FO₈ M + Na 509.1582, M + K 525.1322, found *m/z* 509.1573, 525.1311.

cis- and *trans*-2-(1,3-Dimethoxy-1,3-dioxopropan-2-yl)-6fluoro-4-phenyl-1,2,3,4-tetrahydronaphthalene (5s). The title compound was prepared according to the general procedure from cyclopropane 1b (252 mg, 1.0 mmol), styrene (2a) (624 mg, 6 mmol), and GaCl₃ (176 mg, 1.0 mmol) as a mixture of diastereomers (*cis:trans* = 8:1) in 347 mg yield (82%). The major *cis*-isomer was isolated in pure form by chromatography on a SiO₂ plate.

The following are data for compound cis-5s (major isomer). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3010, 2955, 2928, 1733 (O=CO), 1602, 1590, 1496, 1454, 1437 cm⁻¹. MS (*m*/*z* (rel intens, %)): 356 (1, M^+), 325 (1, M^+ – OCH₃), 224 (100), 209 (12), 196 (15), 183 (8), 159 (8), 146 (35), 133 (32), 115 (7), 91 (100), 59 (15). HRMS: calcd for C₂₁H₂₁FO₄ M + Na 379.1316, M + K 395.1055, found m/z 379.1309, 395.1054. ¹H NMR (CDCl₃, 400.1 MHz): δ 1.65 (ddd, 1H, syn-H(3), ²J = 12.0 Hz, ³J = 12.1, 12.0 Hz), 2.16 (dddd, 1H, anti-H(3), ${}^{2}J = 12.0$ Hz, ${}^{3}J = 5.4$, 2.3 Hz, ${}^{4}J = 2.6$ Hz), 2.63–2.72 (m, 1H, H(2)), 2.71-2.79 (m, 1H, anti-H(1)), 2.89 (ddd, 1H, syn-H(1), ²J = 14.7 Hz, ${}^{3}I = 4.3 \text{ Hz}, {}^{4}I = 2.6 \text{ Hz}$, 3.37 (d, 1H, CH, ${}^{3}I = 8.3 \text{ Hz}$), 3.72 and 3.77 (both s, 2 × 3H, 2 OMe), 4.07 (br dd, 1H, H(4), ${}^{3}J$ = 12.1 and 5.4 Hz), 6.44 (ddd, 1H, H(5), ${}^{4}J$ = 2.7 and 0.9 Hz, ${}^{3}J_{HF}$ = 10.2 Hz), 6.79 (dddd, 1H, H(7), ${}^{3}J$ = 8.5 Hz, ${}^{4}J$ = 2.7 Hz, ${}^{5}J$ = 0.6 Hz, ${}^{3}J_{HF}$ = 8.4 Hz), 7.03 (dd, 1H, H(8), ${}^{3}J$ = 8.5 Hz, ${}^{4}J_{HF}$ = 5.9 Hz), 7.12–7.16 (m, 2H, 2 o-H), 7.21-7.27 (m, 1H, p-H), 7.28-7.34 (m, 2H, 2 m-H). ¹³C{¹H} NMR (CDCl₃, 100.6 MHz): δ 33.5 (CH₂(1)), 35.1 (CH(2)), 37.9 (CH₂(3)), 47.0 (CH(4)), 52.59 and 52.61 (2OMe), 57.3 (CH), 113.4 (d, CH(7), ${}^{2}J_{CF}$ =21.5 Hz), 115.7 (d, CH(5), ${}^{2}J_{CF}$ =21.4 Hz), 126.8 (*p*-CH), 128.78 and 128.81 (2 o-CH and 2 m-CH), 130.2 (d, CH(8), ³J_{CF} = 7.8 Hz), 131.2 (d, C(8a), ${}^{4}J_{CF}$ = 2.8 Hz), 141.4 (d, C(4a), ${}^{3}J_{CF}$ = 6.7 Hz), 145.5 (*i*-C), 161.2 (d, C(6)F, ${}^{1}J_{CF}$ = 243.6 Hz), 168.7 and 168.8 (2COO). ¹⁹F NMR (CDCl₃, 282.4 MHz): δ –117.6 (ddd, 1F, CF(6), ${}^{3}J_{\rm HF}$ = 10.2 and 8.4 Hz, ${}^{4}J_{\rm HF}$ = 5.9 Hz).

The following are data for compound *trans*-**5s** (minor isomer). ¹H NMR (CDCl₃, 400.1 MHz): δ 1.97–2.02 (m, 2H, CH₂(3)), 2.58–2.74 (m, 2H, H(2) and *syn*-H(1)), 2.94–3.04 (m, 1H, *anti*-H(1)), 3.35 (d, 1H, CH, ³*J* = 8.2 Hz), 3.66 and 3.70 (both s, 2 × 3H, 2 OMe), 4.24 (dd, 1H, H(4), ³*J* ≈ 5.3 and 5.3 Hz), 6.64 (dd, 1H, H(5), ⁴*J* = 2.7 Hz, ³*J*_{HF} = 9.7 Hz), 6.86 (ddd, 1H, H(7), ³*J* = 8.3 Hz, ⁴*J* = 2.7 Hz, ³*J*_{HF} = 8.4 Hz), 7.09 (dd, 1H, H(8), ³*J* = 8.3 Hz, ⁴*J*_{HF} = 6.2 Hz), 7.21–7.34 (m, 5H, Ph).

cis- and *trans*-2-(1,3-Dimethoxy-1,3-dioxopropan-2-yl)-6chloro-4-phenyl-1,2,3,4-tetrahydronaphthalene (5t). The title compound was prepared according to the general procedure from cyclopropane 1c (200 mg, 0.75 mmol), styrene (2a) (624 mg, 6.0 mmol), and GaCl₃ (132 mg, 0.75 mmol) as a mixture of diastereomers (*cis*:trans = 9:1) in 195 mg yield (70%). The major *cis*-isomer was isolated in pure form by chromatography on a SiO₂ plate.

The following are data for compound *cis*-**5t** (major isomer). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3012, 2955, 2929, 1733 (O==CO), 1596, 1485, 1454, 1436 cm⁻¹. MS (*m*/*z* (rel intens, %)): 372 (6, M⁺), 341 (6, M⁺ – OCH₃), 240 (100), 205 (29), 178 (15), 162 (5), 91 (2). HRMS: calcd for C₂₁H₂₁ClO₄ M + Na 395.1021, M + K 411.0760, found *m*/*z* 395.1015, 411.0754. ¹H NMR (CDCl₃, 400.1 MHz): δ 1.65 (ddd, 1H, *syn*-H(3), ²*J* = 12.3 Hz, ³*J* = 12.1, 12.1 Hz), 2.17 (dddd, 1H, *anti*-H(3), ²*J* = 12.3 Hz, ³*J* = 7.9, 5.4 Hz, ⁴*J* = 2.2 Hz), 2.62–2.69 (m, 1H, H(2)), 2.77 (dd, 1H, *anti*-H(1), ²*J* = 13.4 Hz, ³*J* = 11.5 Hz),

2.91 (ddd, 1H, syn-H(1), ${}^{2}J$ = 13.4 Hz, ${}^{3}J$ = 5.7 Hz, ${}^{4}J$ = 2.2 Hz), 3.37 (d, 1H, CH, ${}^{3}J$ = 8.1 Hz), 3.73 and 3.78 (both s, 2 × 3H, 2 OMe), 4.07 (dd, 1H, H(4), ${}^{3}J$ = 12.1 and 5.4 Hz), 6.74 (dd, 1H, H(5), ${}^{4}J$ = 2.0 and 1.0 Hz), 7.02 (br d, 1H, H(8), ${}^{3}J$ = 8.3 Hz), 7.07 (ddd, 1H, H(7), ${}^{3}J$ = 8.3 Hz, ${}^{4}J$ = 2.0 Hz, ${}^{5}J$ = 0.9 Hz), 7.12–7.16 (m, 2H, 2 *o*-H), 7.21–7.27 (m, 1H, *p*-H), 7.28–7.34 (m, 2H, 2 *m*-H). ${}^{13}C{}^{1}H$ NMR (CDCl₃, 100.6 MHz): δ 33.7 (CH₂(1)), 34.9 (CH(2)), 38.1 (CH₂(3)), 46.9 (CH(4)), 52.59 and 52.61 (2OMe), 57.2 (CH), 126.4 (CH(7)), 126.8 (*p*-CH), 128.78 and 128.82 (2 *o*-CH and 2 *m*-CH), 128.8 (CH(5)), 130.2 (CH(8)), 131.7 (C(6)Cl), 134.1 (C(8a)), 141.2 (C(4a)), 145.4 (*i*-C), 168.6 and 168.7 (2COO).

The following are data for compound *trans*-**5t** (minor isomer). ¹H NMR (CDCl₃, 400.1 MHz): δ 1.95–2.01 (m, 2H, CH₂(3)), 2.55–2.72 (m, 2H, H(2) and *syn*-H(1)), 2.99 (dd, 1H, *anti*-H(1), ²*J* = 15.7 Hz, ³*J* = 3.8 Hz), 3.34 (d, 1H, CH, ³*J* = 8.4 Hz), 3.64 and 3.68 (both *s*, 2 × 3H, 2 OMe), 4.23 (dd, 1H, H(4), ³*J* ≈ 5.2 and 5.2 Hz), 6.93 (d, 1H, H(5), ⁴*J* = 2.0 Hz), 6.95–7.35 (m, 7H, 2Ar except H(5)).

cis- and *trans*-2-(1,3-Dimethoxy-1,3-dioxopropan-2-yl)-8chloro-4-phenyl-1,2,3,4-tetrahydronaphthalene (5u). The title compound was prepared according to the general procedure from cyclopropane 1e (150 mg, 0.56 mmol), styrene (2a) (349 mg, 3.36 mmol), and GaCl₃ (133 mg, 0.75 mmol) as a mixture of diastereomers (*cis*:trans = 7:1) in 83 mg yield (40%). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3014, 2955, 2873, 2857, 1734 (O=CO), 1602, 1567, 1494, 1454, 1438, 1375, 1337, 1257 cm⁻¹. MS (*m*/*z* (rel intens, %)): 372 (3, M⁺), 341 (3, M⁺ – OCH₃), 309 (2), 240 (100), 205 (74), 178 (56), 162 (43), 133 (96), 115 (31), 100 (24), 91 (100), 69 (25), 59 (50). HRMS: calcd for C₂₁H₂₁ClO₄ M + Na 395.1021, found *m*/*z* 395.1019.

The following are data for compound *cis*-**5u** (major isomer). ¹H NMR (CDCl₃, 400.1 MHz): δ 1.67 (ddd, 1H, *syn*-H(3), ²*J* = 12.4 Hz, ³*J* = 12.3 and 12.2 Hz), 2.15 (dddd, 1H, *anti*-H(3), ²*J* = 12.4 Hz, ³*J* = 5.3 and 2.3 Hz, ⁴*J* = 2.4 Hz), 2.61 (dd, 1H, *anti*-H(1), ²*J* = 16.3 Hz, ³*J* = 11.8 Hz), 2.66–2.75 (m, 1H, H(2)), 3.16 (ddd, 1H, *syn*-H(1), ²*J* = 16.3 Hz, ³*J* = 4.2 Hz, ⁴*J* = 2.4 Hz), 3.43 (d, 1H, CH, ³*J* = 8.3 Hz), 3.74 and 3.80 (both s, 2 × 3H, 2 OMe), 4.12 (dd, 1H, H(4), ³*J* = 12.3 and 5.3 Hz), 6.66 (ddd, 1H, H(5), ³*J* = 7.9 Hz, ⁴*J* = 1.2 and 1.2 Hz), 6.94 (dd, 1H, H(6), ³*J* = 7.9 and 7.8 Hz), 7.10–7.16 (m, 2H, 2 *o*-H), 7.19 (ddd, 1H, H(7), ³*J* = 7.8 Hz, ⁴*J* = 1.2, ⁵*J* = 1.1 Hz), 7.21–7.27 (m, 1H, *p*-H), 7.27–7.33 (m, 2H, 2 *m*-H). ¹³C{¹H} NMR (CDCl₃, 100.6 MHz): δ 32.0 (CH₂(1)), 34.9 (CH(2)), 37.5 (CH₂(3)), 47.3 (CH(4)), 52.61 and 52.67 (2 OMe), 57.3 (CH), 126.69, 126.72, 127.0, and 128.1 (CH(5), CH(6), CH(7) and *p*-CH), 128.7 and 128.8 (2 *o*-CH and 2 *m*-CH), 133.8, 134.2, 142.0, and 145.9 (C(4a), C(8a), C(8) and *i*-C), 168.71 and 168.76 (2 COO).

The following are data for compound *trans*-**5u** (minor isomer). ¹H NMR (CDCl₃, 400.1 MHz): δ 1.96–2.06 (m, 2H, CH₂(3)), 2.55–2.77 (m, 2H, H(2) and *syn*-H(1)), 3.09–3.17 (m, 1H, *anti*-H(1)), 3.38 (d, 1H, CH, ³*J* = 7.9 Hz), 3.67 and 3.70 (both s, 2 × 3H, 2 OMe), 4.31 (dd, 1H, H(4), ³*J* = 4.8 and 4.8 Hz), 6.90 (br d, 1H, H(5), ³*J* = 7.6 Hz), 6.95–7.00 (m, 2H, 2 *o*-H), 7.05 (dd, 1H, H(6), ³*J* = 7.8 and 7.6 Hz), 7.16–7.34 (m, 4H, H(7), *p*-H and 2 *m*-H).

cis- and *trans*-2-(1,3-Dimethoxy-1,3-dioxopropan-2-yl)-7chloro-4-phenyl-1,2,3,4-tetrahydronaphthalene (5v). The title compound was prepared according to the general procedure from cyclopropane 1d (200 mg, 0.75 mmol), styrene (2a) (468 mg, 4.5 mmol), and GaCl₃ (145 mg, 0.83 mmol) as a mixture of two diastereomers (*cis:trans* = 6:1) in 165 mg yield (59%). The major *cis*isomer was isolated in pure form by chromatography.

The following are data for compound *cis*-**5v** (major isomer). Colorless thick oil. IR (CHCl₃): $\tilde{\nu}$ 3015, 2955, 1733 (O=CO), 1597, 1485, 1454, 1436 cm⁻¹. MS (*m*/*z* (rel intens, %)): 372 (7, M⁺), 341 (8, M⁺ – OCH₃), 240 (100), 215 (5), 205 (51), 178 (29), 162 (13), 133 (22), 115 (6), 91 (22), 59 (13). HRMS: calcd for C₂₁H₂₁ClO₄ M + H 373.1201, M + Na 395.1021, found *m*/*z* 373.1193, 395.1016. ¹H NMR (CDCl₃, 400.1 MHz): δ 1.65 (ddd, 1H, *syn*-H(3), ²*J* = 12.3 Hz, ³*J* = 12.1, 12.1 Hz), 2.18 (dddd, 1H, *anti*-H(3), ²*J* = 12.3 Hz, ³*J* = 5.4, 2.4 Hz, ⁴*J* = 2.0 Hz), 2.63–2.73 (m, 1H, H(2)), 2.74–2.85 (m, 1H, *anti*-H(1)), 2.91 (ddd, 1H, *syn*-H(1), ²*J* = 13.3 Hz, ³*J* = 4.3 Hz, ⁴*J* = 2.0 Hz), 3.37 (d, 1H, CH, ³*J* = 8.2 Hz), 3.74 and 3.78 (both s, 2 × 3H, 2 OMe), 4.07 (dd, 1H, H(4), ³*J* = 12.1 and 5.4 Hz), 6.69 (dd, 1H, H(5),

³*J* = 8.4 Hz, ⁴*J* = 0.7 Hz), 6.97 (dd, 1H, H(6), ³*J* = 8.4 Hz, ⁴*J* = 2.2 Hz), 7.09 (d, 1H, H(8), ⁴*J* = 2.2 Hz), 7.11–7.14 (m, 1H, *p*-H), 7.20–7.27 (m, 2H, 2 *o*-H), 7.27–7.35 (m, 2H, 2 *m*-H). ¹³C{¹H} NMR (CDCl₃, 100.6 MHz): δ 34.0 (CH₂(1)), 34.8 (CH(2)), 38.2 (CH₂(3)), 46.5 (CH(4)), 52.59 and 52.61 (2OMe), 57.2 (CH), 126.3 (CH(6)), 126.7 (*p*-CH), 128.6 (CH(8)), 128.73 and 128.76 (2 *o*-CH and 2 *m*-CH), 130.9 (CH(5)), 131.7 (C(7)Cl), 137.6 (C(8a)), 137.9 (C(4a)), 145.6 (*i*-C), 168.61 and 168.69 (2COO).

The following are data for compound *trans*-**5**v (minor isomer). ¹H NMR (CDCl₃, 400.1 MHz): δ 1.97–2.03 (m, 2H, CH₂(3)), 2.55–2.67 (m, 1H, H(2)), 2.65–2.75 (m, 1H, *syn*-H(1)), 3.01 (dd, 1H, *anti*-H(1), ³*J* = 16.6 and 4.9 Hz), 3.35 (d, 1H, CH, ³*J* = 8.5 Hz), 3.66 and 3.70 (both s, 2 × 3H, 2 OMe), 4.24 (dd, 1H, H(4), ³*J* ≈ 5.1 and 5.1 Hz), 6.85–7.30 (m, 8H, 2Ar).

cis/trans-2-(1,3-Dimethoxy-1,3-dioxopropan-2-yl)-4-phenyl-1,2,3,4-tetrahydroanthracene (5w) and *cis/trans*-2-(1,3-Dimethoxy-1,3-dioxopropan-2-yl)-4-phenyl-1,2,3,4-tetrahydrophenanthrene (5x). The title compounds were prepared according to the general procedure from cyclopropane 1f (150 mg, 0.53 mmol), styrene (2a) (386 mg, 3.71 mmol), and GaCl₃ (93 mg, 0.53 mmol) in 125 mg total yield (62%). Colorless thick oil. HRMS: calcd for $C_{25}H_{24}O_4$ M + H 389.1747, M + Na 411.1567, M + K 427.1306, found *m/z* 389.1738, 411.1571, 427.1305. The compounds obtained were partially separated by column chromatography on silica gel to give a mixture of *cis*-5w and *cis*-5w, pure *trans*-5x, and a mixture of *trans*-5w and *trans*-5x. The calculated yields by NMR are 25% for 5w (*cis:trans* = 1.9:1) and 37% for 5y (*cis:trans* = 1:2.3).

The following are data for compound *cis*-5w (major isomer). ¹H NMR (CDCl₃, 400.1 MHz): δ 1.76 (ddd, 1H, syn-H(3), ²J = 12.6 Hz, ${}^{3}J = 12.5$ and 12.2 Hz), 2.24 (dddd, 1H, anti-H(3), ${}^{2}J = 12.6$ Hz, ${}^{3}J =$ 5.3 and 2.7 Hz, ⁴J = 2.4 Hz), 2.76-2.85 (m, 1H, H(2)), 2.98 (dd, 1H, anti-H(1), ${}^{2}J = 16.1$ Hz, ${}^{3}J = 12.4$ Hz), 3.17 (ddd, 1H, syn-H(1), ${}^{2}J =$ 16.1 Hz, ${}^{3}J = 4.3$ Hz, ${}^{4}J = 2.4$ Hz), 3.41 (d, 1H, CH, ${}^{3}J = 8.7$ Hz), 3.74 and 3.80 (both s, $2 \times 3H$, 2 OMe), 4.28 (dd, 1H, H(4), ${}^{3}J = 12.5$ and 5.3 Hz), 7.21 (s, 1H, H(10)), 7.21-7.26 (m, 2H, 2 o-H), 7.22-7.30 (m, 1H, p-H), 7.29 (dd, 1H, H(7), ${}^{3}J$ = 7.5 and 7.1 Hz), 7.30–7.37 (m, 2H, 2 *m*-H), 7.35 (dd, 1H, H(6), ${}^{3}J$ = 8.2 and 7.1 Hz), 7.53 (d, 1H, H(8), ${}^{3}J = 7.5 Hz$), 7.58 (s, 1H, H(9)), 7.70 (d, 1H, H(5), ${}^{3}J = 8.2$ Hz). ¹³C{¹H} NMR (CDCl₃, 100.6 MHz): δ 34.7 (CH₂(1)), 35.3 (CH(2)), 38.5 (CH₂(3)), 47.3 (CH(4)), 52.6 (2 OMe), 57.5 (CH), 125.2 (CH(7)), 125.6 (CH(6)), 126.6 (p-CH), 127.0 (CH(5)), 127.1 (CH(9)), 127.5 (CH(8)), 128.1 (CH(10)), 128.7 (2 m-CH), 129.0 (2 o-CH), 132.2, 132.3, 134.4, 138.3, and 146.4 (C(4a), C(8a), C(9a), C(10a) and *i*-C), 168.8 (2 COO).

The following are data for compound *trans*-**5x** (minor isomer). ¹H NMR (CDCl₃, 400.1 MHz): δ 2.05–2.18 (m, 2H, CH₂(3)), 2.68–2.78 (m, 1H, H(2)), 2.91 (dd, 1H, *anti*-H(1)), ²*J* = 16.3 Hz, ³*J* = 9.6 Hz), 3.23 (dd, 1H, *syn*-H(1), ²*J* = 16.3 Hz, ³*J* = 5.1 Hz), 3.41 (d, 1H, CH, ³*J* = 8.8 Hz), 3.68 and 3.71 (both s, 2 × 3H, 2 OMe), 4.48 (dd, 1H, H(4), ³*J* = 5.7 and 5.7 Hz), 7.02–7.07 (m, 2H, 2 *o*-H), 7.16–7.24 (m, 1H, *p*-H), 7.23–7.29 (m, 2H, 2 *m*-H), 7.31–7.37 and 7.35–7.41 (both m, 2 × 1H, H(6) and H(7)), 7.42 and 7.63 (both s, 2 × 1H, H(9) and H(10)), 7.60–7.64 and 7.72–7.76 (both m, 2 × 1H, H(5) and H(8)). ¹³C{¹H} NMR (CDCl₃, 100.6 MHz): δ 30.8 (CH(2)), 33.7 and 36.0 (CH₂(1) and CH₂(3)), 43.7 (CH(4))), 52.44 and 52.46 (2 OMe), 56.3 (CH), 125.3, 125.6, 126.2, 127.1, 127.2, 127.5, and 128.5 (7CH(Ar)), 128.4 and 128.8 (2 *o*-CH and 2 *m*-CH), 132.43, 132.47, 134.6, 137.0, and 146.6 (C(4a), C(8a), C(9a), C(10a) and *i*-C), 168.8 (2 COO).

The following are data for compound *cis*-**5x** (minor isomer). ¹H NMR (CDCl₃, 400.1 MHz): δ 1.59 (ddd, 1H, *syn*-H(3), ²*J* = 13.1 Hz, ³*J* = 12.4 and 10.2 Hz), 2.51 (br ddd, 1H, *anti*-H(3), ²*J* = 13.1 Hz, ³*J* = 7.7 and 2.7 Hz), 2.61–2.69 (m, 1H, H(2)), 2.86–3.01 (m, 2H, CH₂(1)), 3.37 (d, 1H, CH, ³*J* = 8.9 Hz), 3.73 and 3.77 (both s, 2 × 3H, 2 OMe), 4.78 (dd, 1H, H(4), ³*J* = 10.2 and 7.4 Hz), 6.96–7.02 (m, 2H, 2 *o*-H), 7.07–7.13 (m, 1H, *p*-H), 7.14 (dd, 1H, H(7), ³*J* = 8.2 and 7.3 Hz), 7.15–7.20 (m, 2H, 2 *m*-H), 7.24 (d, 1H, H(10), ³*J* = 8.4 Hz), 7.28 (dd, 1H, H(6), ³*J* = 8.0 and 7.3 Hz), 7.54 (d, 1H, H(5), ³*J* = 8.2 Hz), 7.67 (d, 1H, H(9), ³*J* = 8.4 Hz), 7.73 (d, 1H, H(8), ³*J* = 8.0 Hz). ¹³C{¹H</sup> NMR (CDCl₃, 100.6 MHz): δ 34.7 (CH(2)), 35.9

(CH₂(1)), 40.9 (CH₂(3)), 44.0 (CH(4)), 52.5 and 52.6 (2 OMe), 57.0 (CH), 124.7 (CH(6)), 125.5 (CH(7)), 125.6 (CH(8)), 125.8 (*p*-CH), 127.2 (CH(9)), 127.4 (2 o-CH), 127.9 (CH(10)), 128.5 (CH(5)), 128.8 (2 *m*-CH), 132.1, 132.7, 133.2, 135.4, and 148.7 (C(4a), C(4b), C(8a), C(10a) and *i*-C), 168.78 and 168.84 (2 COO).

The following are data for compound *trans*-5x (major isomer). Colorless thick oil. HRMS: calcd for C25H24O4 M + H 389.1747, M + Na 411.1567, M + K 427.1306, found m/z 389.1743, 411.1575, 427.1313. ¹H NMR (CDCl₃, 400.1 MHz): δ 2.08 (ddd, 1H, H(3)-a, ²J = 12.5 Hz, ${}^{3}J$ = 12.5 and 5.1 Hz), 2.17 (dddd, 1H, H(3)-b, ${}^{2}J$ = 12.5 Hz, ${}^{3}J = 2.5$ and 1.8 Hz, ${}^{4}J = 1.5$ Hz), 2.57–2.66 (m, 1H, H(2)), 2.90 (dd, 1H, anti-H(1), ${}^{2}J$ = 16.9 Hz, ${}^{3}J$ = 11.5 Hz), 3.16 (ddd, 1H, syn-H(1), ${}^{2}J$ = 16.9 Hz, ${}^{3}J$ = 5.1 Hz, ${}^{4}J$ = 1.5 Hz), 3.35 (d, 1H, CH, ${}^{3}J$ = 7.8 Hz), 3.64 and 3.70 (both s, 2×3 H, 2 OMe), 4.87 (dd, 1H, H(4), $^{3}J =$ 5.1 and 1.8 Hz), 6.97-7.03 (m, 2H, 2 o-H), 7.10-7.17 (m, 1H, p-H), 7.17–7.24 (m, 2H, 2 m-H), 7.26 (br dd, 1H, H(7), ${}^{3}J$ = 8.5 and 6.9 Hz), 7.27 (d, 1H, H(10), ${}^{3}J$ = 8.5 Hz), 7.34 (ddd, 1H, H(6), ${}^{3}J$ = 8.1 and 6.9 Hz, ${}^{4}J$ = 1.2 Hz), 7.61 (d, 1H, H(8), ${}^{3}J$ = 8.5 Hz), 7.70 (d, 1H, H(9), ${}^{3}J$ = 8.5 Hz), 7.77 (br d, 1H, H(5), ${}^{3}J$ = 8.1 Hz). ${}^{13}C{}^{1}H$ NMR (CDCl₃, 100.6 MHz): δ 29.2 (CH(2)), 34.1 and 36.5 (CH₂(1) and CH₂(3)), 41.4 (CH(4)), 52.36 and 52.41 (2 OMe), 57.1 (CH), 124.4 (CH(8)), 124.9 (CH(6)), 126.1 (p-CH), 126.2 (CH(7) or CH(10)), 127.3 (CH(9)), 127.8 (CH(7) or CH(10)), 128.3 (2 m-CH), 128.4 (2 o-CH and CH(5)), 131.8, 132.2, 132.7, 134.2, and 145.8 (C(4a), C(4b), C(8a), C(10a) and i-C), 168.7 and 168.9 (2 COO).

ASSOCIATED CONTENT

S Supporting Information

2D NMR data for the key compounds and NMR spectra for all new compounds. The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.5b01179.

AUTHOR INFORMATION

Corresponding Author

*Phone/fax: +7 499 135 6390. E-mail: tom@ioc.ac.ru.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported by the Russian Science Foundation (Project 14-13-01054).

REFERENCES

(1) Reviews of DACs: (a) Reissig, H. U.; Zimmer, R. Chem. Rev. 2003, 103, 1151. (b) Yu, M.; Pagenkopf, B. L. Tetrahedron 2005, 61, 321. (c) de Simone, F.; Waser, J. Synthesis 2009, 2009, 3353. (d) Carson, C. A.; Kerr, M. A. Chem. Soc. Rev. 2009, 38, 3051. (e) Campbell, M. J.; Johnson, J. S.; Parsons, A. T.; Pohlhaus, P. D.; Sanders, S. D. J. Org. Chem. 2010, 75, 6317. (f) Mel'nikov, M. Ya.; Budynina, E. M.; Ivanova, O. A.; Trushkov, I. V. Mendeleev Commun. 2011, 21, 293. (g) Schneider, T. F.; Kaschel, J.; Werz, D. B. Angew. Chem., Int. Ed. 2014, 53, 5504. (h) de Nanteuil, F.; de Simone, F.; Frei, R.; Benfatti, F.; Serrano, E.; Waser, J. Chem. Commun. 2014, 50, 10912. (i) Novikov, R. A.; Tomilov, Yu. V. Mendeleev Commun. 2015, 25, 1. (j) Cavitt, M. A.; Phun, L. H.; France, S. Chem. Soc. Rev. 2014, 43, 804. (2) Selected recent examples of DAC reactions: (a) Rakhmankulov, E. R.; Ivanov, K. L.; Budynina, E. M.; Ivanova, O. A.; Chagarovskiy, A. O.; Skvortsov, D. A.; Latyshev, G. V.; Trushkov, I. V.; Melnikov, M. Ya. Org. Lett. 2015, 17, 770. (b) Braun, C. M.; Congdon, E. A.; Nolin, K. A. J. Org. Chem. 2015, 80, 1979. (c) Rivero, A. R.; Fernández, I.; Ramirez de Arellano, C.; Sierra, M. A. J. Org. Chem. 2015, 80, 1207. (d) Pandey, A. K.; Ghosh, A.; Banerjee, P. Eur. J. Org. Chem. 2015, 2015, 2517. (e) Zhang, H.-H.; Luo, Y.-C.; Wang, H.-P.; Chen, W.; Xu, P.-F. Org. Lett. 2014, 16, 4896. (f) Zhu, J.; Liang, Y.; Wang, L.; Zheng, Z.-B.; Houk, K. N.; Tang, Y. J. Am. Chem. Soc. 2014, 136, 6900. (g) Ghorai, M. K.; Talukdar, R.; Tiwari, D. P. Org. Lett. 2014, 16,

2204. (h) Racine, S.; de Nanteuil, F.; Serrano, E.; Waser, J. Angew. Chem., Int. Ed. 2014, 53, 8484. (i) Wang, Z.; Ren, J.; Wang, Z. Org. Lett. 2013, 15, 5682. (j) Garve, L. K. B.; Barkawitz, P.; Jones, P. G.; Werz, D. B. Org. Lett. 2014, 16, 5804. (k) Ivanov, K. L.; Villemson, E. V.; Budynina, E. M.; Ivanova, O. A.; Trushkov, I. V.; Melnikov, M. Y. Chem. - Eur. J. 2015, 21, 4975.

(3) 1,2-Dipole reactivity of DACs: (a) Novikov, R. A.; Balakirev, D. O.; Timofeev, V. P.; Tomilov, Yu. V. Organometallics 2012, 31, 8627.
(b) Novikov, R. A.; Tarasova, A. V.; Korolev, V. A.; Timofeev, V. P.; Tomilov, Yu. V. Angew. Chem., Int. Ed. 2014, 53, 3187. (c) Novikov, R. A.; Tarasova, A. V.; Suponitsky, K. Yu.; Tomilov, Yu. V. Mendeleev Commun. 2014, 24, 346. (d) Novikov, R. A.; Tarasova, A. V.; Tomilov, Yu. V. Russ. Chem. Bull. 2014, 63, 2737.

(4) Using GaCl₃ in DAC chemistry: (a) Korotkov, V. S.; Larionov, O. V.; Hofmeister, A.; Magull, J.; de Meijere, A. J. Org. Chem. 2007, 72, 7504. (b) Tomilov, Y. V.; Novikov, R. A.; Nefedov, O. M. Tetrahedron 2010, 66, 9151. (c) Novikov, R. A.; Timofeev, V. P.; Tomilov, Yu. V. J. Org. Chem. 2012, 77, 5993. (d) Novikov, R. A.; Tomilov, Yu. V. Helv. Chim. Acta 2013, 96, 2068. (e) Novikov, R. A.; Korolev, V. A.; Timofeev, V. P.; Tomilov, Y. V. Helv. Chim. Acta 2013, 96, 2068. (e) Novikov, R. A.; Korolev, V. A.; Timofeev, V. P.; Tomilov, Y. V. Tetrahedron Lett. 2011, 52, 4996. (f) Novikov, R. A.; Tomilov, Yu. V.; Nefedov, O. M. Russ. Chem. Bull. 2012, 61, 1917. (g) Novikov, R. A.; Shulishov, E. V.; Tomilov, Yu. V.; Nefedov, O. M. Mendeleev Commun. 2012, 22, 181.

(5) Reactions of DACs with alkenes: (a) Beal, R. B.; Dombroski, M. A.; Snider, B. B. J. Org. Chem. **1986**, *51*, 4391. (b) Shimada, S.; Hashimoto, Y.; Sudo, A.; Hasegawa, M.; Saigo, K. J. Org. Chem. **1992**, *57*, 7126. (c) England, D. B.; Kuss, T. D. O.; Keddy, R. G.; Kerr, M. A. J. Org. Chem. **2001**, *66*, 4704. (d) de Nanteuil, F.; Waser, J. Angew. Chem., Int. Ed. **2011**, *50*, 12075. (e) Qu, J.-P.; Deng, C.; Zhou, J.; Sun, X.-L.; Tang, Y. J. Org. Chem. **2009**, *74*, 7684. (f) Volkova, Y. A.; Budynina, E. M.; Kaplun, A. E.; Ivanova, O. A.; Chagarovskiy, A. O.; Skvortsov, D. A.; Rybakov, V. B.; Trushkov, I. V.; Melnikov, M. Y. Chem. - Eur. J. **2013**, *19*, 6586.

(6) Biologically active compounds with the tetralin skeleton: (a) Fiorentino, A.; D'Abrosca, B.; Pacifico, S.; Natale, A.; Monaco, P. *Phytochemistry* **2006**, *67*, 971. (b) Fiorentino, A.; D'Abrosca, B.; Pacifico, S.; Iacovino, R.; Izzo, A.; Uzzo, P.; Russo, A.; Di Blasio, B.; Monaco, P. *Tetrahedron* **2008**, *64*, 7782. (c) Royer, M.; Eparvier, V.; Thibaut, B.; Stien, D.; Herbette, G.; Beauchene, J. *Phytochemistry* **2010**, *71*, 1708. (d) Piel, J.; Hoang, K.; Moore, B. S. J. Am. Chem. Soc. **2000**, *122*, 5415. (e) Xu, H.; Lv, M.; Tian, X. *Curr. Med. Chem.* **2009**, *16*, 327. (f) Gordaliza, M.; Garcia, P. A.; Miguel del Corral, J. M.; Castro, M. A.; Gomez-Zurita, M. A. *Toxicon* **2004**, *44*, 441.

(7) Chagarovskiy, A. O.; Ivanova, O. A.; Rakhmankulov, E. R.; Budynina, E. M.; Trushkov, I. V.; Melnikov, M. Y. *Adv. Synth. Catal.* **2010**, 352, 3179. Article